Author: "Clinique Saint Augustin" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Clinique Saint Augustin"' showing total 236 results

Start Over Author "Clinique Saint Augustin"

236 results on '"Clinique Saint Augustin"'

1. Covid-19 Respiratory Sequelae French Cohort (PNEUMOCOVID)

Author: Cabinet Medical valenciennes, CH Aix, hopital privé de bois bernard, Clinique La Croix du Sud, University Hospital, Bordeaux, Hopital Forcilles, Hopital d'instructions des armées, Hôpital Européen Marseille, Rennes University Hospital, Clinique Saint Augustin, Delafontaine Hospital, Centre Hospitalier Universitaire de Saint Etienne, Centre Hospitalier de Troyes, Centre Hospitalier le Mans, University Hospital, Clermont-Ferrand, and University Hospital, Tours
Published: 2024

2. French Cohort Evaluating the effectiveneSs of Atrioventricular Synchrony by the micRa AV (AV-CESAR)

Author: CHU de Tours, European Georges Pompidou Hospital, Hôpital privé Clairval - Marseille, Clinique Pasteur Toulouse, University Hospital, Bordeaux, Infirmerie Protestante Lyon, Institut Jacques Cartier - Massy, University Hospital, Grenoble, Hôpital de la Timone, University Hospital, Toulouse, Hopital Prive Saint Martin - Bordeaux, Hospices Civils de Lyon, CHU de Rouen - Accueil, University Hospital, Caen, Médipôle Lyon-Villeurbanne, Hospital Ambroise Paré Paris, Clinique Saint Augustin - Bordeaux, Rennes University Hospital, Clinique de la Sauvegarde - Lyon, University Hospital of Saint-Etienne, Hôpital Privé de Parly II - Le Chesnay, Institut Mutualiste Montsouris, Centre Hospitalier Universitaire, Amiens, University Hospital, Clermont-Ferrand, Centre Hospitalier Régional et Universitaire de Brest, Poitiers University Hospital, Clinique Saint-Gatien - Tours, CHU de Reims, Centre Hospitalier Universitaire de Besancon, Centre Hospitalier Universitaire Dijon, Hôpital Privé de Lille Métropole, University Hospital, Montpellier, University Hospital, Strasbourg, France, Nantes University Hospital, Centre Cardio-Thoracique de Monaco, Hospital St. Joseph, Marseille, France, Centre Hospitalier Régional Metz-Thionville, Centre Hospitalier Annecy Genevois, Clinique du Millenaire, University Hospital, Limoges, Clinique Saint Pierre - Perpignan, Bichat Hospital, Universite de La Reunion, CHU de Lille, Institute Arnault Tzanck, France, Hôpital Privé Les Franciscaines, CHU de Fort de France - Martinique, Henri Mondor University Hospital, University Hospital, Angers, Centre Hospitalier de Lens, and Central Hospital, Nancy, France
Published: 2023

3. S-ICD French Cohort Study (HONEST) (HONEST)

Author: Centre Cardio-Thoracique de Monaco, Centre Cardiologique du Nord, Groupe Hospitalier de la Region de Mulhouse et Sud Alsace, Centre Hospitalier Annecy Genevois, Centre Hospitalier Bretagne Atlantique, Centre Hospitalier William Morey - Chalon sur Saône, Centre Hospitalier du Pays d'Aix, Centre Hospitalier Albi, Centre Hospitalier Antibes - Juan Les Pins, Centre Hospitalier Argenteuil, Centre Hospitalier Henri Duffaut - Avignon, Centre Hospitalier Auxerre, Centre Hospitalier de Bastia, Centre Hospitalier de Bigorre - Tarbes, Boulogne sur Mer Hospital Center, Centre Hospitalier de Carcassonne, Centre hospitalier de Chambéry, Centre Hospitalier of Chartres, Centre Hospitalier de Compiègne, Centre Hospitalier de Haguenau (Est France), Centre hospitalier de la Polynésie française - Papeete, Centre Hospitalier de La Rochelle, Centre Hospitalier de Lens, Ch Mont de Marsan, Centre Hospitalier de Montauban, Centre Hospitalier de Moulins Yzeure, Centre Hospitalier de PAU, Centre Hospitalier de Perigueux, Centre hospitalier de Perpignan, Centre Hospitalier de Roubaix, Centre Hospitalier de Saint-Brieuc, Centre Hospitalier de Troyes, Centre Hospitalier de Valence, Centre Hospitalier de Valenciennes, Centre Hospitalier Departemental Vendee, Centre Hospitalier le Mans, Centre Hospitalier Eure-Seine, Centre Hospitalier Henri Mondor - Aurillac, Centre Hospitalier Intercommunal Castres-Mazamet, Centre Hospitalier Jacques Cœur - Bourges, Centre Hospitalier Libourne, Centre Hospitalier Princesse Grace, Centre Hospitalier Régional d'Orléans, Hôpital NOVO, Centre Hospitalier Rodez, Centre Hospitalier Saint Joseph Saint Luc de Lyon, Central Hospital Saint Quentin, Centre Hospitalier Saintonge - Saintes, Centre Hospitalier Sud Francilien, Centre Hospitalier Territorial- Nouméa, Centre Hospitalier Toulon, Centre Hospitalier Universitaire de Saint Etienne, Poissy-Saint Germain Hospital, CHR Mercy - Metz, Amiens University Hospital, University Hospital, Angers, Centre Hospitalier Universitaire de Besancon, University Hospital, Clermont-Ferrand, University Hospital, Bordeaux, University Hospital, Caen, Centre Hospitalier Universitaire de la Réunion, CHU de Lille, University Hospital, Limoges, University Hospital, Montpellier, CHU de Nancy, Nantes University Hospital, Poitiers University Hospital, CHU de Rouen - Accueil, University Hospital, Strasbourg, France, University Hospital, Toulouse, CHU de Tours, Centre Hospitalier Universitaire Dijon, Centre Hospitalier Felix Guyon, University Hospital, Grenoble, Centre Hospitalier Régional et Universitaire de Brest, Centre Hospitalier Universitaire de Nice, CHU de Reims, CHU Rennes - Hopital Pontchaillou, Clinique Alleray Labrouste, CMC Ambroise Paré, Clinique Belledonne - Grenoble, Clinique Claude Bernard - Metz, Clinique du Millenaire, Clinique du Parc - Castelnau le Lez - Montpellier, Clinique du Tonkin - Lyon - Villeurbane, Clinique Saint-Hilaire, Clinique Les Fontaines - Melun, Clinique Louis Pasteur Essey-lès-Nancy, Clinique Oreliance - Orléans, Clinique Pasteur Toulouse, Clinique Rhône Durance - Avignon, Clinique Saint Augustin - Bordeaux, Clinique Saint Georges - Nice, Clinique Saint Pierre - Perpignan, Clinique Saint Vincent - Besancon, Clinique Saint-Gatien - Tours, Clinique Saint Joseph, Liège, GCS Cardiologie - Bayonne, Groupe Hospitalier de Bretagne Sud, Groupe Hospitalier du Havre, Raincy Montfermeil Hospital Group, European Georges Pompidou Hospital, Hopital Antoine Beclere, Bichat Hospital, Centre Hospitalier Universitaire de Nīmes, Hôpital de la Croix-Rousse, Hôpital de la Timone, Henri Mondor University Hospital, Hôpital Marie Lannelongue - Le Plessis Robinson, Hôpital Necker-Enfants Malades, University Hospital, Marseille, Hopital Nord Franche-Comte, Hôpital Privé Arnault Tzanck - Mougins - Sophia Antipolis, Hôpital privé Bois Bernard - Lens, Hôpital privé Clairval - Marseille, Hôpital privé Claude Galien - Quincy-sous-Sénart, Hôpital Privé de la Loire- Saint Etienne, Hôpital Privé de Parly II - Le Chesnay, Hôpital privé du Confluent - Nantes, Hôpital privé Le Bois - Lille MetropoleHôpital Privé Les Franciscaines - Nîmes, Hôpital Privé Marseille - Beauregard, Hôpital privé Saint-Martin - Caen, Hospital St. Joseph, Marseille, France, Hôpital Saint Philibert - Lille - GHICL, Hospices Civils de Lyon, Institut Jacques Cartier - Massy, Institut Mutualiste Montsouris, Pitié-Salpêtrière Hospital, Pôle Santé République, Pôle Santé Sud - Le Mans, Polyclinique Les Fleurs - Toulon, Polyclinique Lyon-Nord - Rillieux, Polyclinique Reims-Bezannes-Courlancy, Polyclinique Saint Laurent - Rennes, Polyclinique Vauban - Valencienne, and Amiens SAS
Published: 2022

4. Recommandations sur la gestion du risque et la prise en charge urologique du patient adulte atteint de dysraphisme spinal (spina bifida)

Author: Manunta, Andréa, Peyronnet, Benoît, Olivari-Philiponnet, Camille, Chartier-Kastler, Emmanuel J., Saussine, Christian C., Phé, Véronique, Robain, Gilberte, Denys, Pierre, Even, Alexia, Samson, Emmanuelle, Grise, Phillippe, Karsenty, G., Hascoet, Juliette, Castel-Lacanal, Evelyne, Charvier, Kathleen F., Guinet-Lacoste, Amandine, Chesnel, Camille, Amarenco, Gérard, Haffner, F., Haddad, Mirna, Le Normand, Loïc, Perrouin-Verbe, Marie Aimée, Perrouin-Verbe, Brigitte, de Seze, Marianne, Ruffion, Alain, Gamé, Xavier, CHU Pontchaillou [Rennes], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Hôpital Raymond Poincaré [Garches], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Strasbourg, CHU Tenon [AP-HP], Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), CHU Rouen, Normandie Université (NU), Chirurgie urologique et transplantation rénale [Hôpital de la Conception - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Service Médecine physique et de réadaptation [CHU Toulouse], Pôle Neurosciences [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Médecine Physique et Réadaptation [Hôpital Henry Gabrielle - Lyon], Hôpital Henry Gabrielle [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Groupe de RecherchE CliniquE en Neuro-urologie [CHU Tenon] (GRC 1 - GREEN ), CHU Marseille, Centre hospitalier universitaire de Nantes (CHU Nantes), Clinique Saint Augustin, and Hospices Civils de Lyon (HCL)
Subjects: Quality of life, Complications, [SDV]Life Sciences [q-bio], Urology, Urinary incontinence, Neurogenic, Spinal dysraphism, Spina bifida, Urinary bladder
Abstract: International audience; Introduction: Improved life expectancy and prenatal screening have changed the demographics of spina bifida (spinal dysraphism) which has presently become a disease of adulthood. Urinary disorders affect almost all patients with spinal dysraphism and are still the leading cause of mortality in these patients. The aim of this work was to establish recommendations for urological management that take into account the specificities of the spina bifida population. Materials and methods: National Diagnosis and Management Guidelines (PNDS) were drafted within the framework of the French Rare Diseases Plan at the initiative of the Centre de Référence Maladies Rares Spina Bifida - Dysraphismes of Rennes University Hospital. It is a collaborative work involving experts from different specialties, mainly urologists and rehabilitation physicians. We conducted a systematic search of the literature in French and English in the various fields covered by these recommendations in the MEDLINE database. In accordance with the methodology recommended by the authorities (Guide_methodologique_pnds.pdf, 2006), proposed recommendations were drafted on the basis of this literature review and then submitted to a review group until a consensus was reached. Results: Bladder dysfunctions induced by spinal dysraphism are multiple and varied and evolve over time. Management must be individually adapted and take into account all the patient's problems, and is therefore necessarily multi-disciplinary. Self-catheterisation is the appropriate micturition method for more than half of the patients and must sometimes be combined with treatments aimed at suppressing any neurogenic detrusor overactivity (NDO) or compliance alteration (anticholinergics, intra-detrusor botulinum toxin). Resort to surgery is sometimes necessary either after failure of non-invasive treatments (e.g. bladder augmentation in case of NDO resistant to pharmacological treatment), or as a first line treatment in the absence of other non-invasive alternatives (e.g. aponeurotic suburethral tape or artificial urinary sphincter for sphincter insufficiency; urinary diversion by ileal conduit if self-catheterisation is impossible). Conclusion: Spinal dysraphism is a complex pathology with multiple neurological, orthopedic, gastrointestinal and urological involvement. The management of bladder and bowel dysfunctions must continue throughout the life of these patients and must be integrated into a multidisciplinary context.
Published: 2023

5. Development and evaluation of the accuracy of an indicator of the appropriateness of interventional cardiology generated from a French registry

Author: Florence Francis-Oliviero, Pierre Coste, Emilie Lesaine, Corinne Perez, François Casteigt, Jean-Marie Clerc, Nicolas Delarche, Akil Hassan, Bernard Larnaudie, Jean-Louis Leymarie, Louis-Rachid Salmi, Florence Saillour-Glenisson, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, CHU Bordeaux [Bordeaux], Polyclinique Bordeaux Nord Aquitaine, CENTRE HOSPITALIER PÉRIGUEUX (CHP), Centre hospitalier de Pau, CHU Mont de Marsan, Clinique Saint Augustin, Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED), and Université de Bordeaux (UB)
Subjects: Angioplasty, Public Health, Environmental and Occupational Health, Angiography, Appropriateness, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Practice registry
Abstract: Background Development of appropriateness indicators of medical interventions has become a major quality-of-care issue, especially in the domain of interventional cardiology (IC). The objective of this study was to develop and evaluate the accuracy of an indicator of the appropriateness of interventional cardiology acts (invasive coronary angiographies (ICA) and percutaneous coronary interventions (PCI)) in patients with coronary stable disease and silent ischemia, automated from a French registry. Methods All ICA and PCI recorded in a Regional IC Registry (ACIRA) and operated for a stable coronary artery disease or silent ischemia from January 1st to December 31th 2013 in eight IC hospitals of Aquitaine, southwestern France, were included. The indicator was developed to reflect European guidelines. Classification of appropriateness by the indicator, measured on the registry database, was compared to the classification of a reference standard (expert judgment applied through complete record review) on a random sample of 300 interventions. Accuracy parameters were estimated. A second version of the indicator was defined, based on the analysis of false negative and positive results, and its accuracy estimated. Results The second indicator accuracy was: sensitivity 63.5% (95% confidence interval CI [51.7–75.3]), specificity 76.0% (95%CI [70.4–81.6]), PPV 43.0% (95% CI [33.0–53.0]) and NPV 88.0% (95% CI [83.4–92.6]). When stratified on the type of act, parameters were better for ICA alone than for PCI. Conclusions Accuracy of the indicator should raise with improvement of database quality. Despite its average accuracy, it is already used as a benchmark indicator for cardiologists. It is sent annually to each IC center with value of the indicator at the region level to allow a comparison.
Published: 2022

6. Guidelines on enhanced recovery after cardiac surgery under cardiopulmonary bypass or off-pump

Author: Paul-Michel Mertes, Michel Kindo, Julien Amour, Christophe Baufreton, Lionel Camilleri, Thierry Caus, Didier Chatel, Bernard Cholley, Alain Curtil, Jean-Philippe Grimaud, Rémi Houel, Fehmi Kattou, Jean-Luc Fellahi, Catherine Guidon, Pierre-Grégoire Guinot, Guillaume Lebreton, Sandrine Marguerite, Alexandre Ouattara, Sophie Provenchère Fruithiot, Bertrand Rozec, Jean-Philippe Verhoye, André Vincentelli, Hélène Charbonneau, Les Hôpitaux Universitaires de Strasbourg (HUS), Nouvel Hôpital Civil de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Hôpital Privé Jacques Cartier [Massy], MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Clermont-Ferrand, CHU Amiens-Picardie, Nouvelle Clinique de Tours Saint Gatien-Alliance [Tours] (CTSGA), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Innovations thérapeutiques en hémostase (IThEM - U1140), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Clinique de la Sauvegarde [Lyon], Clinique Saint Augustin, Hôpital Saint-Joseph [Marseille], Institut Mutualiste de Montsouris (IMM), Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Hôpital de la Timone [CHU - APHM] (TIMONE), Aix Marseille Université (AMU), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer (LabEx LipSTIC), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Gustave Roussy (IGR)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-Université de Montpellier (UM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut Agro Dijon, Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases, Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Bordeaux [Bordeaux], Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier universitaire de Nantes (CHU Nantes), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Hôpital Pontchaillou, CHU Lille, Université de Lille, Clinique Pasteur [Toulouse], DESSAIVRE, Louise, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Innovations thérapeutiques en hémostase = Innovative Therapies in Haemostasis (IThEM - U1140), École Pratique des Hautes Études (EPHE), and UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-Université de Montpellier (UM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)
Subjects: Adult, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Cardiopulmonary Bypass, Critical Care, Coronary Artery Bypass, Off-Pump, off pump cardiac surgery, General Medicine, Cardiac surgery, Guidelines, Length of Stay, Critical Care and Intensive Care Medicine, Enhanced recovery after surgery (ERAS), Anesthesiology and Pain Medicine, Anesthesiology, Patient Satisfaction, Humans, Anesthesia, Cardiac Surgical Procedures, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; Objective: To provide recommendations for enhanced recovery after cardiac surgery (ERACS) based on a multimodal perioperative medicine approach in adult cardiac surgery patients with the aim of improving patient satisfaction, reducing postoperative mortality and morbidity, and reducing the length of hospital stay. Design: A consensus committee of 20 experts from the French Society of Anaesthesia and Intensive Care Medicine (Societe francaise d'anesthesie et de reanimation, SFAR) and the French Society of Thoracic and Cardiovascular Surgery (Societe francaise de chirurgie thoracique et cardio-vasculaire, SFCTCV) was convened. A formal conflict-of-interest policy was developed at the onset of the process and enforced throughout. The entire guideline process was conducted independently of any industry funding. The authors were advised to follow the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to guide the assessment of the quality of evidence. Methods: Six fields were defined: (1) selection of the patient pathway and its information; (2) preoperative management and rehabilitation; (3) anaesthesia and analgesia for cardiac surgery; (4) surgical strategy for cardiac surgery and bypass management; (5) patient blood management; and (6) postoperative enhanced recovery. For each field, the objective of the recommendations was to answer questions formulated according to the PICO model (Population, Intervention, Comparison, Outcome). Based on these questions, an extensive bibliographic search was carried out and analyses were performed using the GRADE approach. The recommendations were formulated according to the GRADE methodology and then voted on by all the experts according to the GRADE grid method. Results: The SFAR/SFCTCV guideline panel provided 33 recommendations on the management of patients undergoing cardiac surgery under cardiopulmonary bypass or off-pump. After three rounds of voting and several amendments, a strong agreement was reached for the 33 recommendations. Of these recommendations, 10 have a high level of evidence (7 GRADE 1+ and 3 GRADE 1-); 19 have a moderate level of evidence (15 GRADE 2+ and 4 GRADE 2-); and 4 are expert opinions. Finally, no recommendations were provided for 3 questions. Conclusions: Strong agreement existed among the experts to provide recommendations to optimise the complete perioperative management of patients undergoing cardiac surgery. (C) 2022 The Authors. Published by Elsevier Masson SAS on behalf of Societe francaise d'anesthesie et de reanimation (Sfar).
Published: 2022

7. Optical coherence tomography to guide percutaneous coronary intervention of the left main coronary artery: the LEMON study

Author: Christophe Caussin, Nicolas Meneveau, Radwane Hakim, Mohamed Mehdi Boussaada, Thierry Lefèvre, Géraud Souteyrand, Matthieu Godin, Pascal Motreff, Guillaume Cayla, Nicolas Amabile, Frederic Casassus, Imane Bagdadi, Grégoire Rangé, Institut Mutualiste de Montsouris (IMM), Hôpitaux de Chartres [Chartres], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Clinique St Hilaire ( Service de Cardiologie, Rouen), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( EA 3920) (PCVP / CARDIO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Clinique Saint Augustin, Institut Cardiovasculaire Paris Sud, and Centre Jacques Cartier
Subjects: medicine.medical_specialty, medicine.medical_treatment, MESH: Ultrasonography, Interventional, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Angioplasty, Intravascular ultrasound, medicine, Clinical endpoint, MESH: Coronary Vessels, 030212 general & internal medicine, cardiovascular diseases, MESH: Coronary Artery Disease, MESH: Treatment Outcome, MESH: Aged, MESH: Humans, medicine.diagnostic_test, business.industry, Percutaneous coronary intervention, Stent, medicine.disease, MESH: Pilot Projects, MESH: Coronary Angiography, MESH: Male, MESH: Prospective Studies, 3. Good health, Stenosis, MESH: Stents, MESH: Tomography, Optical Coherence, surgical procedures, operative, Conventional PCI, Radiology, Cardiology and Cardiovascular Medicine, business, MESH: Female, MESH: Percutaneous Coronary Intervention, TIMI
Abstract: International audience; Background: Intravascular ultrasound (IVUS)-guided PCI improves the prognosis of left main stem (LMS) PCI and is currently recommended by international guidelines. Although OCT resolution is greater than that of IVUS, this tool is not yet recommended in LMS angioplasty due to the absence of data.Aims: This pilot study aimed to analyse the feasibility, safety and impact of OCT-guided LMS PCI.Methods: This prospective, multicentre trial investigated whether patients might benefit from OCT-guided PCI for mid/distal LMS according to a pre-specified protocol. The primary endpoint was procedural success defined as follows: residual angiographic stenosis
Published: 2021

8. Online training on how to diagnose anoperineal lesions of Crohn's disease: Do pictures matter? A nationwide randomized study

Author: Laurent Siproudhis, P. Roumeguère, Paul Benfredj, C. Bord, E. Pommaret, A Nouts, Laurent Abramowitz, Guillaume Bonnaud, Dominique Bouchard, C Geffrier, F Devulder, V. de Parades, J M Didelot, T. Higuero, Ghislain Staumont, Jean-David Zeitoun, Guillaume Bouguen, P Marteau, F. Pigot, X. Lesage, P Petit, Nadia Fathallah, Clinique Beau Soleil [Montpellier], Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Clinique Saint Augustin, CHU Saint-Antoine [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: medicine.medical_specialty, [SDV]Life Sciences [q-bio], Perineum, law.invention, Education, Distance, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Randomized controlled trial, law, Medical Illustration, Skin Ulcer, Photography, Clinical endpoint, Humans, Rectal Fistula, Medicine, In patient, Anus Diseases, Crohn's disease, Electronic Mail, Hepatology, business.industry, Gastroenterology, medicine.disease, Abscess, 3. Good health, Erythema, 030220 oncology & carcinogenesis, Physical therapy, Online teaching, 030211 gastroenterology & hepatology, Educational Measurement, France, business
Abstract: Summary Any gastroenterologist must be trained to properly diagnose anoperineal lesions in patients with Crohn's disease (APLOC). The aim of this study was to establish whether adding pictures would improve teaching effectiveness of the diagnosis of APLOC to French gastroenterology trainees. Method Trainees were asked to answer a first web-based survey consisting of evaluating 12 pictures of APLOC with a closed answer questionnaire. They were then randomized in 2 groups. Group A received an online teaching with typical pictures and APLOC definitions and group B definitions only. Trainees were asked again seven days later to answer a second survey with 12 other pictures of APLOC and 14 experts also answered this survey. Diagnostic scores were expressed in %. The primary endpoint was the comparison of the score of survey 2 between the two groups of trainees. Secondary endpoints were to compare results of survey 2 between trainees of both groups and experts, and assess diagnosis of each lesion. Results Two hundred fourty eight trainees among 465 answered survey 1, and 195 survey 2. The diagnostic score was 71.9% for groups A and B and 74.6% for experts (differences NS). After training diagnosis of ulceration was 72% for group A and 72.9% for group B, fistulae 85.2% versus 85.8%, erythema 44.1% vs. 55.6%, anoperineal scars 67.5% vs. 65.6%, and abscess 100% (differences NS). Conclusion There was no difference between the two teaching methods. Further research should be performed aiming at improving teaching material and quotation baremes.
Published: 2019

9. Intradetrusor Injections of Botulinum Toxin A in Adults with Spinal Dysraphism

Author: Marie-Aimée Perrouin-Verbe, Xavier Biardeau, Pierre Denys, Loic Lenormand, Maximilien Baron, Jean-Nicolas Cornu, Christian Saussine, Emmanuel Chartier-Kastler, Xavier Gamé, Gilles Karsenty, Marianne de Sèze, Brigitte Schurch, Véronique Phé, Genulf, Jean-Michel Boutin, Gérard Amarenco, Alexia Even, Benoit Peyronnet, Grégoire Capon, Andrea Manunta, Juliette Hascoet, CHU Pontchaillou [Rennes], Hôpital Raymond Poincaré [AP-HP], service d'urologie [CHU Bordeaux], CHU Bordeaux [Bordeaux], Clinique Saint Augustin, Service d'Urologie, andrologie et transplantation rénale [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'urologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Université de Nantes (UN), Service d'urologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Université de Strasbourg (UNISTRA), Service d'Urologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'urologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Chirurgie urologique et transplantation rénale [Hôpital de la Conception - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Université de Lausanne (UNIL), Service de médecine physique et réadaptation [CHU Raymond-Poincaré], Physiologie et physiopathologie de la motricité chez l'homme, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR70-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Fédérale Toulouse Midi-Pyrénées, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Tenon [AP-HP], Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lausanne = University of Lausanne (UNIL), and Université de Toulouse (UT)
Subjects: Male, medicine.medical_specialty, type A, Multivariate analysis, Spinal dysraphism, Urology, 030232 urology & nephrology, overactive, Urinary incontinence, Injections, Intralesional, Severity of Illness Index, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Botulinum toxin a, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, medicine, Clinical endpoint, Humans, Botulinum Toxins, Type A, Retrospective Studies, Analysis of Variance, 030219 obstetrics & reproductive medicine, Urinary bladder, Urinary Bladder, Overactive, business.industry, Spina bifida, adult, Prognosis, botulinum toxins, medicine.disease, 3. Good health, Treatment Outcome, medicine.anatomical_structure, Multivariate Analysis, Quality of Life, spinal dysraphism, Patient Compliance, Detrusor pressure, Female, medicine.symptom, business, urinary bladder, urodynamics
Abstract: International audience; Purpose:The aim of the current study was to determine the outcomes of botulinum toxin A intradetrusor injections in adult patients with spina bifida.Materials and methods:All patients with spinal dysraphism who underwent intradetrusor injections of botulinum toxin A from 2002 to 2016 at a total of 14 centers were retrospectively included in analysis. The primary end point was the global success of injections, defined subjectively as the combination of urgency, urinary incontinence and detrusor overactivity/low bladder compliance resolution. Univariate and multivariate analysis was performed to seek predictors of global success.Results:A total of 125 patients were included in study. The global success rate of the first injection was 62.3% with resolution of urinary incontinence in 73.5% of patients. All urodynamic parameters had improved significantly by 6 to 8 weeks compared to baseline, including maximum detrusor pressure (–12 cm H 2O, p
Published: 2018

10. Robust augmented reality registration method for localization of solid organs’ tumors using CT-derived virtual biomechanical model and fluorescent fiducials

Author: Renato V. Soares, Galyna Shabat, Bohdan Andreiuk, Nazim Haouchine, Stéphane Cotin, Andrey S. Klymchenko, Michele Diana, Seong-Ho Kong, Bruno Marques, Jacques Marescaux, Thierry Piechaud, Seoul National University Hospital, L'Institut hospitalo-universitaire de Strasbourg (IHU Strasbourg), Institut National de Recherche en Informatique et en Automatique (Inria)-l'Institut de Recherche contre les Cancers de l'Appareil Digestif (IRCAD)-Les Hôpitaux Universitaires de Strasbourg (HUS)-La Fédération des Crédits Mutuels Centre Est (FCMCE)-L'Association pour la Recherche contre le Cancer (ARC)-La société Karl STORZ, Laboratoire de Biophotonique et Pharmacologie - UMR 7213 (LBP), Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS), Computational Anatomy and Simulation for Medicine (MIMESIS), Inria Nancy - Grand Est, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche Contre les Cancers de l'Appareil Digestif-European Institute of Telesurgery (IRCAD/EITS), Clinique Saint Augustin, and SOFA
Subjects: Models, Anatomic, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, Swine, Finite Element Analysis, [SDV.CAN]Life Sciences [q-bio]/Cancer, In Vitro Techniques, Kidney, 03 medical and health sciences, DICOM, Imaging, Three-Dimensional, 0302 clinical medicine, Software, Optical imaging, Fiducial Markers, Neoplasms, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, Animals, Medicine, Computer vision, Fluorescent Dyes, business.industry, Virtual Reality, Finite element method, Biomechanical Phenomena, Visualization, Surgery, Computer-Assisted, 030220 oncology & carcinogenesis, Laparoscopy, 030211 gastroenterology & hepatology, Surgery, Augmented reality, Biomechanical model, Artificial intelligence, Tomography, X-Ray Computed, business, Fiducial marker
Abstract: Augmented reality (AR) is the fusion of computer-generated and real-time images. AR can be used in surgery as a navigation tool, by creating a patient-specific virtual model through 3D software manipulation of DICOM imaging (e.g., CT scan). The virtual model can be superimposed to real-time images enabling transparency visualization of internal anatomy and accurate localization of tumors. However, the 3D model is rigid and does not take into account inner structures' deformations. We present a concept of automated AR registration, while the organs undergo deformation during surgical manipulation, based on finite element modeling (FEM) coupled with optical imaging of fluorescent surface fiducials.Two 10 × 1 mm wires (pseudo-tumors) and six 10 × 0.9 mm fluorescent fiducials were placed in ex vivo porcine kidneys (n = 10). Biomechanical FEM-based models were generated from CT scan. Kidneys were deformed and the shape changes were identified by tracking the fiducials, using a near-infrared optical system. The changes were registered automatically with the virtual model, which was deformed accordingly. Accuracy of prediction of pseudo-tumors' location was evaluated with a CT scan in the deformed status (ground truth). In vivo: fluorescent fiducials were inserted under ultrasound guidance in the kidney of one pig, followed by a CT scan. The FEM-based virtual model was superimposed on laparoscopic images by automatic registration of the fiducials.Biomechanical models were successfully generated and accurately superimposed on optical images. The mean measured distance between the estimated tumor by biomechanical propagation and the scanned tumor (ground truth) was 0.84 ± 0.42 mm. All fiducials were successfully placed in in vivo kidney and well visualized in near-infrared mode enabling accurate automatic registration of the virtual model on the laparoscopic images.Our preliminary experiments showed the potential of a biomechanical model with fluorescent fiducials to propagate the deformation of solid organs' surface to their inner structures including tumors with good accuracy and automatized robust tracking.
Published: 2016

11. Antibioprophylaxie et bilan urodynamique : recommandations de bonne pratique par consensus formalisé

Author: E. Marit Ducamp, G. Robain, Jean-Ralph Zahar, Céline Pulcini, Jean-Christophe Lucet, P. Denys, Albert Sotto, Didier Lepelletier, X. Gamé, Xavier Deffieux, Louis Bernard, François Caron, Brigitte Fatton, Eric Senneville, Manuel Etienne, Loic Lenormand, Gabriel Birgand, Gérard Amarenco, Michel Cosson, Aurélien Dinh, Emmanuel Chartier-Kastler, F. Bruyère, Christine Lawrence, J-F Hermieu, C. Egrot, Xavier Fritel, M. de Sèze, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Raymond Poincaré [AP-HP], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre hospitalier universitaire de Nantes (CHU Nantes), Service d'urologie [Tours], Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centrale Lille, Hôpital Antoine Béclère, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Charles Nicolle [Rouen], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital de Rangueil, CHU Toulouse [Toulouse], Service de bactériologie et hygiène hospitalière [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Clinique Saint Augustin, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Hôpital Rothschild [AP-HP], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Avicenne [AP-HP], Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)
Subjects: Infective risk, medicine.medical_specialty, Bacteriuria, Urology, Recommandations, 030232 urology & nephrology, Guidelines, Consensus method, Bilan urodynamique, 03 medical and health sciences, 0302 clinical medicine, Infection urinaire, medicine, Antibioprophylaxie, Antibiotic prophylaxis, ComputingMilieux_MISCELLANEOUS, Gynecology, Urinary tract infection, business.industry, 3. Good health, Risque infectieux, Clinical Practice, Urodynamic studies, Bactériurie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, 030217 neurology & neurosurgery
Abstract: Resume Objectif L’objectif de ce travail etait d’emettre des recommandations de bonne pratique concernant l’antibioprophylaxie dans le cadre d’un BUD. Materiels et methodes Des recommandations ont ete elaborees par un groupe de pilotage multidisciplinaire avant d’etre validees par une methode de consensus formalisee par un groupe multidisciplinaire de 12 experts (groupe de cotation). Elles ont ensuite ete validees par un groupe de lecture (experts differents du groupe de cotation). Resultats La realisation d’un examen cytobacteriologique des urines (ECBU) avec antibiogramme est recommandee dans les jours precedant le BUD, pour tous les patients (Accord fort). Chez les sujets ne presentant pas de pathologie neurologique, les facteurs de risque d’infection urinaire apres BUD sont l’âge > 70 ans, les infections urinaires iteratives et un residu post-mictionnel > 100 ml. Chez les sujets ayant une pathologie neurologique, les facteurs de risque d’infection urinaire apres BUD sont les infections urinaires iteratives, le reflux vesico-ureteral, une pression vesicale premictionnelle elevee > 40 cmH2O. Si l’ECBU pre-BUD est sterile, en l’absence de facteur de risque d’infection urinaire, aucune antibioprophylaxie n’est recommandee (Accord fort). Si l’ECBU pre-BUD est sterile mais qu’il existe un ou plusieurs facteur(s) de risque d’infection urinaire, une antibioprophylaxie peut etre, ou non, proposee. Si une antibioprophylaxie est decidee, il est recommande de prescrire une prise unique de fosfomycine-trometamol (3 g par voie orale), deux heures avant le BUD (Accord fort). En cas de colonisation urinaire pre-BUD, une antibiotherapie peut etre, ou non, prescrite (indecision). Si une antibiotherapie est proposee, elle doit etre adaptee a l’antibiogramme de la (ou des) bacterie(s) identifiee(s) (Accord fort). Elle doit etre debutee la veille de l’examen, et etre interrompue apres celui-ci (Accord fort) (sauf pour la fosfomycine-trometamol pour laquelle une seule prise la veille du BUD est necessaire et suffisante) (Accord fort). En cas d’infection urinaire pre-BUD, celle-ci doit etre traitee et l’examen doit etre reporte (Accord fort). Les regles proposees ici n’ont pas a etre modifiees chez les patients porteurs de prothese de hanche ou de genou (Accord fort). Par ailleurs, aucune prophylaxie de l’endocardite infectieuse n’est necessaire, y compris chez les patients porteurs de cardiopathie valvulaire a haut risque (Accord fort). Conclusion Ces nouvelles recommandations devraient contribuer a harmoniser les pratiques et a limiter l’exposition aux antibiotiques. Niveau de preuve 4.
Published: 2018

12. Prospective, randomized, controlled, open-label study to compare efficacy of a mineral-rich solution vs normal saline after complete ethmoidectomy

Author: Geoffrey Mortuaire, Roger Jankowski, Philippe Boudard, Bertrand Merino, Guillaume de Bonnecaze, Christian Debry, Olivier Malard, Virginie Escabasse, Sylvain Morinière, Laurence Bordenave, Ludovic de Gabory, Cécile Rumeau, CHU Bordeaux [Bordeaux], CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Université de Bordeaux (UB), Centre Hospitalier Intercommunal de Créteil (CHIC), Clinique Saint Augustin, CHU Toulouse [Toulouse], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Strasbourg, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Lille, Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and univOAK, Archive ouverte
Subjects: Male, medicine.medical_specialty, Mucociliary clearance, medicine.medical_treatment, Lund–Kennedy endoscopic score, 03 medical and health sciences, 0302 clinical medicine, Nasal Polyps, Quality of life, Nasal polyposis, Chlorides, Ethmoid Sinus, Medicine, Humans, Prospective Studies, Sinusitis, 030223 otorhinolaryngology, Therapeutic Irrigation, Saline, Nose, Administration, Intranasal, Rhinitis, Postoperative Care, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, Ethmoidectomy, Endoscopy, General Medicine, Middle Aged, Rhinology, 3. Good health, Nasal irrigation, medicine.anatomical_structure, Sodium Bicarbonate, Chronic rhinosinusitis, Otorhinolaryngology, Tolerability, Patient Satisfaction, 030220 oncology & carcinogenesis, Anesthesia, Quality of Life, Female, Saline Solution, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Purposes: The purpose of this study was to compare the efficacy of a mineral-rich solution vs normal saline solution (0.9% NaCl) following endoscopic complete bilateral ethmoidectomy. Methods: This was a prospective, multicenter, randomized, controlled, open-label trial in subjects suffering from steroid-resistant sinonasal polyposis. Adults performed 4 nasal irrigations of mineral or saline solutions daily for 28 days. Evaluations included subject-reported RHINO quality of life (QoL) and NOSE scores, tolerability, and satisfaction, the Lund-Kennedy endoscopic score and assessments of crusting, secretions and mucociliary clearance (rhinoscintigraphy). Results: A total of 189 subjects were randomized. Clinically relevant improvements (> 20 points) in RhinoQOL and NOSE scores were measured in both groups without any significant inter-group difference. Among the subjects with impaired RhinoQOL at pre-inclusion, the change in Impact-RhinoQOL score was significantly superior in mineral-rich vs saline solution at day 21 (p = 0.028) and day 28 (p = 0.027). The Lund-Kennedy score continuously improved in both groups earlier with the mineral-rich solution. Crusts were significantly fewer in number and less severe/obstructive in patients receiving mineral-rich vs saline solution at day 7 (p = 0.026) and day 14 (p = 0.016). Furthermore, secretions disappeared significantly more quickly and were less thick/purulent with mineral-rich solution at day 14 (p = 0.002) and day 21 (p = 0.043). Less epistaxis was reported in the mineral vs saline solution (p = 0.008 at day 21). Conclusions: Our findings indicate that the composition of a nasal irrigation solution influences endoscopic scores and QoL after sinus surgery for patients over 60, those with an initially poor QoL and higher symptom score, and smokers.
Published: 2018

13. Accuracy of elastic fusion biopsy in daily practice: Results of a multicenter study of 2115 patients

Author: Giuseppe Simone, Mauro Ciccariello, M. Rouprêt, Pierre Mozer, Alessandro Giacobbe, Pardeep Kumar, Thierry Piechaud, Paolo Gontero, Antonio Carbone, Olivier Rouvière, Mariaconsiglia Ferriero, Eduard Baco, Antonio Luigi Pastore, Giuseppe Fasolis, Vito Lacetera, Emanuela Altobelli, Marine Dubreuil-Chambardel, Roland Van Velthoven, Giancarlo Marra, A. Cantiani, J.L. Descotes, Valerio Beatrici, Valerio Forte, Alexandre Peltier, Marco Oderda, Gaelle Fiard, Giovanni Muto, Jean Baptiste Roche, David Eldred-Evans, Rocco Papalia, Simone Albisinni, Service de chirurgie, CHU Grenoble-Hôpital Michallon, Gestes Medico-chirurgicaux Assistés par Ordinateur (TIMC-IMAG-GMCAO), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Division of Urology, San Lazzaro Hospital, Clinique Saint Augustin, Service d'urologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Edouard Herriot [CHU - HCL], and Hospices Civils de Lyon (HCL)
Subjects: Koelis, Adult, Image-Guided Biopsy, Male, medicine.medical_specialty, Multivariate analysis, Urology, [SDV]Life Sciences [q-bio], 030232 urology & nephrology, Magnetic Resonance Imaging, Interventional, Multimodal Imaging, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Prostate, Predictive Value of Tests, Biopsy, medicine, Humans, Sampling (medicine), Stage (cooking), Fusion Biopsy, Multiparametric Magnetic Resonance Imaging, Ultrasonography, Interventional, Aged, Retrospective Studies, targeted, Aged, 80 and over, medicine.diagnostic_test, accuracy, business.industry, random, Prostatic Neoplasms, Reproducibility of Results, fusion biopsy, Middle Aged, Prostate-Specific Antigen, medicine.disease, 3. Good health, Europe, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Feasibility Studies, Radiology, Biopsy, Large-Core Needle, business
Abstract: International audience; OBJECTIVES:To assess the accuracy of Koelis fusion biopsy for the detection of prostate cancer and clinically significant prostate cancer in the everyday practice.METHODS:We retrospectively enrolled 2115 patients from 15 institutions in four European countries undergoing transrectal Koelis fusion biopsy from 2010 to 2017. A variable number of target (usually 2-4) and random cores (usually 10-14) were carried out, depending on the clinical case and institution habits. The overall and clinically significant prostate cancer detection rates were assessed, evaluating the diagnostic role of additional random biopsies. The cancer detection rate was correlated to multiparametric magnetic resonance imaging features and clinical variables.RESULTS:The mean number of targeted and random cores taken were 3.9 (standard deviation 2.1) and 10.5 (standard deviation 5.0), respectively. The cancer detection rate of Koelis biopsies was 58% for all cancers and 43% for clinically significant prostate cancer. The performance of additional, random cores improved the cancer detection rate of 13% for all cancers (P < 0.001) and 9% for clinically significant prostate cancer (P < 0.001). Prostate cancer was detected in 31%, 66% and 89% of patients with lesions scored as Prostate Imaging Reporting and Data System 3, 4 and 5, respectively. Clinical stage and Prostate Imaging Reporting and Data System score were predictors of prostate cancer detection in multivariate analyses. Prostate-specific antigen was associated with prostate cancer detection only for clinically significant prostate cancer.CONCLUSIONS:Koelis fusion biopsy offers a good cancer detection rate, which is increased in patients with a high Prostate Imaging Reporting and Data System score and clinical stage. The performance of additional, random cores seems unavoidable for correct sampling. In our experience, the Prostate Imaging Reporting and Data System score and clinical stage are predictors of prostate cancer and clinically significant prostate cancer detection; prostate-specific antigen is associated only with clinically significant prostate cancer detection, and a higher number of biopsy cores are not associated with a higher cancer detection rate.
Published: 2018

14. Temporal Trends in Transcatheter Aortic Valve Replacement in France: FRANCE 2 to FRANCE TAVI

Author: Auffret, Vincent, Lefevre, Thierry, Belle, Eric, Eltchaninoff, Hélène, Iung, Bernard, Koning, René, Motreff, Pascal, Leprince, Pascal, Philippe, Philippe, Manigold, Thibaut, Souteyrand, Geraud, Boulmier, Dominique, Joly, Patrick, Pinaud, Frédéric, Himbert, Dominique, Collet, Philippe, Rioufol, Gilles, Ghostine, Said, Bar, Olivier, Dibie, Alain, Champagnac, Didier, Leroux, Lionel, Collet, Frédéric, Teiger, Emmanuel, Darremont, Olivier, Folliguet, Thierry, Leclercq, Florence, Lhermusier, Thibault, Olhmann, Patrick, Huret, Bruno, Lorgis, Luc, Drogoul, Laurent, Bertrand, Bernard, Spaulding, Christian, Quilliet, Laurent, Cuisset, Thomas, Delomez, Max, Beygui, Farzin, Claudel, Philippe, Hepp, Alain, Jégou, Arnaud, Gommeaux, Antoine, Mirode, Anfani, Christiaens, Luc, Christophe, Christophe, Cassat, Claude, Metz, Damien, MANGIN, Lionel, Isaaz, Karl, Jacquemin, Laurent, Guyon, Philippe, Pouillot, Christophe, Makowski, Serge, Bataille, Vincent, Rodes-Cabau, Josep, Gilard, Martine, Laskar, Marc, Chevalier, Bernard, Hovasse, Thomas, Donzeau Gouge, Patrick, Farge, Arnaud, Romano, Mauro, Bertrand, Bertrand, Bouvier, Erik, Bauchart, Jean, Delhaye, Cédric, Houpe, David, Robert, Robert, Leroy, Fabrice, Sudre, Arnaud, Juthier, Francis, Koussa, Mohamed, Modine, Thomas, Rousse, Natacha, Auffray, Jean, Richard, Richard, Berland, Jacques, Godin, Mathieu, Bessou, Jean, Letocart, Vincent, Roussel, Jean, Combaret, Nicolas, d’Ostrevy, Nicolas, Innorta, Andrea, Clerfond, Guillaume, Vorilhon, Charles, Bedossa, Marc, Leurent, Guillaume, Anselmi, Amedeo, Harmouche, Majid, Donal, Erwan, Bille, Jacques, Houel, Rémi, Abi Khalil, Wissam, Delepine, Stéphane, Fouquet, Olivier, Roule, Frédéric, Abtan, Jérémie, Urena, Marina, Alkhoder, Soleiman, Ghodbane, Walid, Arangalage, Dimitri, Brochet, Eric, Goublaire, Coppelia, Choussat, Rémi, Lebreton, Guillaume, Mastrioanni, Chiro, Dauphin, Raphaël, Dubreuil, Olivier, Durand de Gevigney, Guy, Finet, Gérard, Harbaoui, Brahim, Ranc, Sylvain, Farhat, Fadi, Jegaden, Olivier, Obadia, Jean, Pozzi, Matteo, Ghostine, Saïd, Fradi, Sahbi, Azmoun, Alexandre, Kauffmann, Martin, Blanchard, Didier, Chassaing, Stephan, Chatel, Didier, Le Page, Olivier, Tauran, Arnaud, Bruere, Didier, Bodson, Laurent, Meurisse, Yvon, Seemann, Aurélie, AMABILE, NICOLAS, Simon, Simon, Drieu, Luc, Ohanessian, Alice, Veugeois, Aurélie, Debauchez, Matthieu, Zannis, Konstantinos, Czitrom, Daniel, Diakov, Chrystelle, Raoux, François, Lienhart, Yves, Staat, Patrick, Zouaghi, Oualid, Doisy, Vincent, Frieh, Philippe, Wautot, Fabrice, Dementhon, Julie, Garrier, Olivier, Jamal, Fadi, Leroux, Pierre, Casassus, Frédéric, Séguy, Benjamin, Barandon, Laurent, Labrousse, Louis, Peltan, Julien, Cornolle, Claire, Dijos, Marina, Lafitte, Stephane, Bayet, Gilles, Charmasson, Claude, Vaillant, Alain, Vicat, Jacques, Giacomoni, Marie Paule, Bergoend, Eric, Zerbib, Céline, Louis Leymarie, Jean, Clerc, Philippe, Choukroun, Emmanuel, Elia, Nicolas, Grimaud, Philippe, Guibaud, Philippe, Wroblewski, Stéphane, Abergel, Eric, Bogino, Emmanuel, Dehant, Patrick, Simon, Marc, Angioi, Michel, Lemoine, Julien, Lemoine, Simon, Popovic, Batric, Maureira, Pablo, Huttin, Olivier, Selton Suty, Christine, Cayla, Guillaume, Delseny, Delphine, Levy, Gilles, Maupas, Eric, Rivalland, François, Robert, Gabriel, Schmutz, Laurent, Targosz, Frédéric, Albat, Bernard, Dubar, Arnaud, Durrleman, Nicolas, Gandet, Thomas, Munos, Emmanuel, Cade, Stéphane, Cransac, Frédéric, Bouisset, Frédéric, Grunenwald, Etienne, Bertrand, Marc, Fournier, Pauline, Morel, Olivier, Ohlmann, Patrick, Kindo, Michel, Hoang, Minh Tam, Petit, Hélène, Samet, Hafida, Trinh, Anne, Lecoq, Guillaume, Morelle, Jean François, Richard, Pascal, Derieux, Thierry, Monier, Emmanuel, Joret, Cédric, Bouchot, Olivier, Meyer, Pierre, Lopez, Stéphane, Tapia, Michel, Teboul, Jacques, Elbeze, Pierre, Mihoubi, Alain, Vanzetto, Gérald, Wittenberg, Olivier, Bach, Vincent, Martin, Cécile, Sauier, Carole, Casset, Charlotte, Castellant, Philippe, Bezon, Eric, Choplain, Jean, Kallifa, Ahmed, Nasr, Bahaa, Jobic, Yannick, Lafont, Antoine, Pagny, Jean, Abi Akar, Ramzi, Fabiani, Jean, Zegdi, Rachid, Berrebi, Alain, Puscas, Tania, Desveaux, Bernard, Ivanes, Fabrice, Bourguignon, Thierry, Aupy, Blandine, Perault, Romain, Bonnet, Jean, Lambert, Marc, Grisoli, Dominique, Jaussaud, Nicolas, Salaün, Erwan, Laghzaoui, Amine, Savoye, Christine, Bignon, Mathieu, Roule, Vincent, Sabatier, Rémy, Ivascau, Calin, Saplacan, Vladimir, Saloux, Eric, Bouchayer, Damien, Tremeau, Guillaume, Diab, Camille, Lapeze, Joel, Pelissier, Franck, Sassard, Thomas, Matz, Catherine, Monsarrat, Nicolas, Carel, Ivan, Sibellas, Franck, Curtil, Alain, Dambrin, Grégoire, Favereau, Xavier, Ghorayeb, Gabriel, Guesnier, Laurent, Khoury, Wassim, Pouzet, Bruno, Vaislic, Claude, Cheikh-Khelifa, Riadh, Hilpert, Loïc, Maribas, Philippe, Hannebicque, Gery, Hochart, Philippe, Paris, Marc, Pecheux, Max, Fabre, Olivier, Leborgne, Laurent, Peltier, Marcel, Le Breton, Hervé, Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], Hôpital Privé Jacques Cartier [Massy], Pole Cardio-vasculaire et pulmonaire [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires (RNMCD - U1011), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de cardiologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de cardiologie [CHU Bichat], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot, Sorbonne Paris Cité, Clinique St Hilaire ( Service de Cardiologie, Rouen), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Image Science for Interventional Techniques (ISIT), Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université-Centre National de la Recherche Scientifique (CNRS), Service de Chirurgie cardiaque et thoracique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Cardiologie [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Saint-Joseph [Marseille], Service de chirurgie cardio-vasculaire et thoracique, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de cardiologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut de cardiologie [CHU Pitié-Salpêtrière], Hôpital Cardiovasculaire Louis Pradel, Hospices Civils de Lyon (HCL), Centre Chirurgical Marie Lannelongue (CCML), Clinique St Gatien et Groupe Athérome Cardiologie Interventionnelle/SF, Clinique St Gatien, Institut Mutualiste de Montsouris (IMM), Clinique du Tonkin, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Hôpital Privé Clairval [Marseille], Centre d'Investigation Clinique Henri Mondor (CIC Henri Mondor), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Clinique Saint Augustin, Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de cardiologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de cardiologie [Toulouse], CHU Strasbourg, Hôpital Privé Saint Martin Caen, Service de Cardiologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut Arnaud Tzanck, Centre Hospitalier Universitaire [Grenoble] (CHU), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Cardiologie (CHU Trousseau, Tours), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre de Biologie pour la Gestion des Populations (UMR CBGP), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Université de Montpellier (UM)-Institut de Recherche pour le Développement (IRD [France-Sud])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut Agro - Montpellier SupAgro, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Nanomédecine Régénérative (NanoRegMed), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Polyclinic du Bois, Service de cardiologie et de pathologie vasculaire [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Infirmerie Protestante Lyon Caluire, parent, Clinique de la Sauvegarde [Lyon], Parly II Private Hospital, Le Chesnay, Hôpital privé Bois-Bernard, Service de Cardiologie [Amiens], CHU Amiens-Picardie, Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Hôpital Dupuytren [CHU Limoges], Hôpital universitaire Robert Debré [Reims], Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Hôpital Nord (Saint Etienne), Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Centre cardiologique du Nord (CCN), Clinique Sainte Clotilde, Hôpital Ambroise Paré [AP-HP], Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Université Laval [Québec] (ULaval), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Unité de Taphonomie médico-légale et Anatomie - ULR 7367 (UTML&A), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hémostase et pathologie cardiovasculaire, EA2693-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, chirurgie thoracique et cardio-vasculaire, Service de chirurgie cardiaque, Service de chirurgie thoracique cardiaque et vasculaire [Rennes] = Thoracic and Cardiovascular Surgery [Rennes], Microbiology Institute of CHUV, Service de Cardiologie de l'hopital de la Croix Rousse, Department of Hemodynamics and Interventional Cardiology, Institut National de la Santé et de la Recherche Médicale (INSERM), Cardiology Department, European Society of Hypertension Excellence Center, Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de chirurgie cardiaque et transplantation, Hôpital Louis Pradel [CHU - HCL], Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pôle Cardiologie Interventionnelle / Coro-scanner / IRM Cardiaque, Clinique Saint Gatien, Hôpital nord, St Etienne, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département de cardiologie, CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], Adaptation cardiovasculaire à l'ischemie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Chirurgie cardio-vasculaire, Service de Cardiologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], École de chirurgie, faculté de médecine de Nancy, Imagerie Adaptative Diagnostique et Interventionnelle (IADI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de chirurgie thoracique et cardio-vasculaire, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve-Université de Montpellier (UM), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), European Synchrotron Radiation Facility (ESRF), Service de Cardiologie (BREST - Cardio), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service d'urologie, Clinique Cardiologie et Hypertension Artérielle, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Clinique de chirurgie cardiaque, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Service de Cardiologie, Brest, Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Développement artériel, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Gynécologie‑Obstétrique, Signalisation, électrophysiologie et imagerie des lésions d’ischémie-reperfusion myocardique (SEILIRM), Normandie Université (NU)-Normandie Université (NU), Service de cardiologie et maladies vasculaires [CHU de Rennes], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Gabriel Montpied (CHU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Henri Mondor-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Pathologie cardiaque, Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], CHU Dijon, Rayonnement Synchrotron et Recherche Medicale (RSRM), Université Joseph Fourier - Grenoble 1 (UJF)-European Synchrotron Radiation Facility (ESRF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Cardiologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Epidémiologie et Biostatistique, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)-Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Universitaire de Clermont-Ferrand, Service de chirurgie thoracique cardiaque et vasculaire [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Service de Chirurgie Thoracique et Cardiovasculaire [CHU Pitié-Salpêtrière], Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Sorbonne Université, Hôpital Arnaud de Villeneuve-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Hôpital Paule de Viguier, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre chirurgical Marie Lannelongue, Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Centre international d'études supérieures en sciences agronomiques (Montpellier SupAgro)-Université de Montpellier (UM)-Institut de Recherche pour le Développement (IRD [France-Sud])-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire Traitement du Signal et de l'Image ( LTSI ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de cardiologie [Rouen], CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), Clinique St Hilaire ( Service de Cardiologie, Rouen ), CHU Gabriel Montpied ( CHU ), Assistance publique - Hôpitaux de Paris - AP-HP (FRANCE), CHU Angers, Hospices Civils de Lyon ( HCL ), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre d'Investigation Clinique Henri Mondor ( CIC Henri Mondor ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Institut Mutualiste de Montsouris ( IMM ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Rayonnement Synchrotron et Recherche Medicale ( RSRM ), Université Joseph Fourier - Grenoble 1 ( UJF ) -ESRF-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Paris-Centre de Recherche Cardiovasculaire ( PARCC - U970 ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Nutrition, obésité et risque thrombotique ( NORT ), Aix Marseille Université ( AMU ) -Institut National de la Recherche Agronomique ( INRA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Centre hospitalier universitaire de Poitiers ( CHU Poitiers ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Épidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Universitaire de Cardiologie et de Pneumologie de Québec ( IUCPQ ), Université Laval, Optimisation des régulations physiologiques ( ORPHY (EA 4324) ), Université de Brest ( UBO ) -Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ) -Institut Brestois Santé Agro Matière ( IBSAM ), Université de Brest ( UBO ) -Université de Brest ( UBO ), Unité de Taphonomie médico-légale ( UTML ), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), EA2693-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Lille, Droit et Santé, Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Hôpital Louis Pradel [CHU - HCL], Cardiovasculaire, métabolisme, diabétologie et nutrition ( CarMeN ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hospices Civils de Lyon ( HCL ) -Institut National des Sciences Appliquées de Lyon ( INSA Lyon ), Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Institut National de la Recherche Agronomique ( INRA ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Imagerie Adaptative Diagnostique et Interventionnelle ( IADI ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Lorraine ( UL ), Centre Hospitalier Régional Universitaire de Nîmes ( CHRU Nîmes ), Université Montpellier 1 ( UM1 ) -Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Arnaud de Villeneuve, Institut des Maladies Métaboliques et Cardiovasculaires ( I2MC ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), European Synchrotron Radiation Facility ( ESRF ), Service de Cardiologie ( BREST - Cardio ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Centre hospitalier universitaire de Nantes ( CHU Nantes ), Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-Hôpital Michallon, Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble, Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Hôpital de la Cavale Blanche - CHRU Brest ( CHU - BREST ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Signalisation, électrophysiologie et imagerie des lésions d’ischémie-reperfusion myocardique ( SEILIRM ), Université de Caen Normandie ( UNICAEN ), Départment de cardiologie [Caen], Normandie Université ( NU ) -Normandie Université ( NU ) -CHU Caen, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 (RNMCD), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service Cardiologie [CHU Toulouse], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service Gynécologie [CHU Toulouse], Pôle Femme-Mère-Couple [CHU Toulouse], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Unité de Taphonomie médico-légale (UTML), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, and Université Grenoble Alpes (UGA)
Subjects: [ SDV ] Life Sciences [q-bio], [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV]Life Sciences [q-bio], transfemoral, national registry, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, outcomes, pacemaker
Abstract: International audience; Background - Transcatheter aortic valve replacement (TAVR) is standard therapy for patients with severe aortic stenosis who are at high surgical risk. However, national data regarding procedural characteristics and clinical outcomes over time are limited. Objectives - The aim of this study was to assess nationwide performance trends and clinical outcomes of TAVR during a 6-year period. Methods - TAVRs performed in 48 centers across France between January 2013 and December 2015 were prospectively included in the FRANCE TAVI (French Transcatheter Aortic Valve Implantation) registry. Findings were further compared with those reported from the FRANCE 2 (French Aortic National CoreValve and Edwards 2) registry, which captured all TAVRs performed from January 2010 to January 2012 across 34 centers. Results - A total of 12,804 patients from FRANCE TAVI and 4,165 patients from FRANCE 2 were included in this analysis. The median age of patients was 84.6 years, and 49.7% were men. FRANCE TAVI participants were older but at lower surgical risk (median logistic European System for Cardiac Operative Risk Evaluation [EuroSCORE]: 15.0% vs. 18.4%; p < 0.001). More than 80% of patients in FRANCE TAVI underwent transfemoral TAVR. Transesophageal echocardiography guidance decreased from 60.7% to 32.3% of cases, whereas more recent procedures were increasingly performed in hybrid operating rooms (15.8% vs. 35.7%). Rates of Valve Academic Research Consortium-defined device success increased from 95.3% in FRANCE 2 to 96.8% in FRANCE TAVI (p < 0.001). In-hospital and 30-day mortality rates were 4.4% and 5.4%, respectively, in FRANCE TAVI compared with 8.2% and 10.1%, respectively, in FRANCE 2 (p
Published: 2017

15. Sequential Proximal Optimizing Technique in Provisional Bifurcation Stenting With Everolimus-Eluting Bioresorbable Vascular Scaffold: Fractal Coronary Bifurcation Bench for Comparative Test Between Absorb and XIENCE Xpedition

Author: Derimay, F, Souteyrand, G., MOTREFF, P., Guering, P., Pilet, P., Ohayon, Jacques, Darremont, O., Rioufol, G., Finet, Gérard, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Clermont-Ferrand, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Polytech Annecy-Chambéry (EPU [Ecole Polytechnique Universitaire de l'Université de Savoie]), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Dynamique Cellulaire et Tissulaire- Interdisciplinarité, Modèles & Microscopies (TIMC-IMAG-DyCTiM), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Clinique Saint Augustin, Hôpital Louis Pradel [CHU - HCL], Claude Bernard University, Centre Hospitalier Lyon Sud, Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), and Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)
Subjects: [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2016

16. Assessment of cardiac resynchronisation therapy in patients with wide QRS and non-specific intraventricular conduction delay: rationale and design of the multicentre randomised NICD-CRT study

Author: Stéphane Garrigue, Pierre Bordachar, Romain Eschalier, Antoine Da Costa, Bruno Pereira, Benoit Guy-Moyat, Sylvain Ploux, Jean-Baptiste Gourraud, Pierre Mondoly, Christophe Leclercq, Pascal Defaye, Daniel Gras, Nicolas Clementy, Image Science for Interventional Techniques (ISIT), Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université-Centre National de la Recherche Scientifique (CNRS), IHU-LIRYC, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux], CHU Clermont-Ferrand, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU St Etienne, Centre Hospitalier Universitaire [Grenoble] (CHU), Clinique Saint Augustin, Centre hospitalier universitaire de Nantes (CHU Nantes), Nouvelles Cliniques Nantaises, CHU Limoges, CHU Pontchaillou [Rennes], Service de cardiologie [Toulouse], Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Service Cardiologie [CHU Toulouse], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
Subjects: Male, Pacemaker, Artificial, medicine.medical_treatment, efficacy, 030204 cardiovascular system & hematology, Cardiovascular Medicine, Cardiac Resynchronization Therapy, Electrocardiography, Ventricular Dysfunction, Left, 0302 clinical medicine, Clinical Protocols, Clinical endpoint, Protocol, Medicine, 030212 general & internal medicine, Prospective Studies, Ejection fraction, medicine.diagnostic_test, Left bundle branch block, General Medicine, Middle Aged, QRS morphology, 3. Good health, Defibrillators, Implantable, Treatment Outcome, Research Design, Cardiology, cardiovascular system, Female, Adult, medicine.medical_specialty, Bundle-Branch Block, Cardiac resynchronization therapy, 03 medical and health sciences, QRS complex, Double-Blind Method, Internal medicine, bundle branch block, Humans, cardiovascular diseases, Aged, Heart Failure, Bundle branch block, business.industry, Patient Selection, Arrhythmias, Cardiac, Stroke Volume, medicine.disease, Surgery, Heart failure, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Introduction Cardiac resynchronisation therapy (CRT) was initially developed to treat patients with left bundle branch block (LBBB). However, many patients with heart failure have a widened QRS but neither left-BBB nor right-BBB; this is called non-specific intraventricular conduction delay (NICD). It is unclear whether CRT is effective in this subgroup of patients. Methods and analysis The NICD-CRT study is a prospective, double-blind, randomised (1:1), parallel-arm, multicentre trial comparing the effects of CRT in patients with heart failure, a reduced left ventricular ejection fraction (LVEF
Published: 2016

17. Development of a standardised training curriculum for robotic surgery: a consensus statement from an international multidisciplinary group of experts

Author: Hendrik Van Poppel, Ronny Abaza, Michael Stoeckle, Joan Palou, Christophe Vaessen, Jacques Hubert, Xavier Cathelineau, Rajesh Ahlawat, Vipul R. Patel, Joachim W. Thüroff, Timothy O. Wilson, Ben Challacombe, Maurice Stephan Michel, Thomas E. Ahlering, Ben Van Cleynenbreugel, Rafael Sanchez-Salas, Christian Wagner, Reenam S. Khan, Alessandro Volpe, Jean Etienne Terrier, Alexandre Mottrie, Henk G. van der Poel, Pierre Thierry Piechaud, Prokar Dasgupta, Catherine Lovegrove, Kamran Ahmed, Francesco Montorsi, Jorn H Witt, Declan G. Murphy, Stefan Siemer, P. Coloby, Eric Barret, Pascal Rischmann, Peter Wiklund, Göran Ahlgren, Walter Artibani, Muhammad Shamim Khan, Jens-Uwe Stolzenburg, Manfred P. Wirth, Ahmed, Kamran, Khan, Reenam, Mottrie, Alexandre, Lovegrove, Catherine, Abaza, Ronny, Ahlawat, Rajesh, Ahlering, Thoma, Ahlgren, Goran, Artibani, Walter, Barret, Eric, Cathelineau, Xavier, Challacombe, Ben, Coloby, Patrick, Khan Muhammad, S., Hubert, Jacque, Michel Maurice, Stephan, Montorsi, Francesco, Murphy, Declan, Palou, Joan, Patel, Vipul, Piechaud Pierre, Thierry, Van Poppel, Hendrik, Rischmann, Pascal, Sanchez Salas, Rafael, Siemer, Stefan, Stoeckle, Michael, Stolzenburg Jens, Uwe, Terrier Jean, Etienne, Thueroff Joachim, W., Vaessen, Christophe, Van der Poel Henk, G., Van Cleynenbreugel, Ben, Volpe, Alessandro, Wagner, Christian, Wiklund, Peter, Wilson, Timothy, Wirth, Manfred, Witt, Joern, Dasgupta, Prokar, UL, IADI, Centre for Transplantation, King's College London (MRC), Guy's Hospital [London], OLVG Hospital, Ohio State University [Columbus] (OSU), Medanta [The Medicity], University of California [Irvine] (UC Irvine), University of California (UC), Skane University Hospital [Lund], Azienda ospedaliera universitaria integrata di Verona [Italy], Service d'urologie [Institut Mutualiste Montsouris], Institut Mutualiste de Montsouris (IMM), Service d'urologie [CH René Dubos Pontoise], Centre Hospitalier René Dubos [Pontoise], Imagerie Adaptative Diagnostique et Interventionnelle (IADI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Urologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), University Hospital Mannheim, Department of urology, Università Vita-Salute San Raffaele, Peter MacCallum Cancer Centre, Peter MacCallum Cancer Center, The Royal Melbourne Hospital, servicio de urologia, Fundación Puigvert, Florida Hospital Celebration Health, Clinique Saint Augustin, University Hospitals Leuven [Leuven], Département d'Urologie-Andrologie et Transplantation Rénale [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Universitätsklinikum des Saarlandes, Department of Urology [Leipzig], Universität Leipzig [Leipzig], Service d'urologie et de transplantation rénale [Suresnes], Hôpital Foch [Suresnes], Universitätsklinikum Ulm - University Hospital of Ulm, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Netherlands Cancer Institute (NKI), Antoni van Leeuwenhoek Hospital, University of Eastern Piedmont, St. Antonius-Hospital Gronau, Department of Oncology-Pathology [Karolinska Institutet], Karolinska Institutet [Stockholm], City of Hope Medical Center, Universitätsklinikum Carl Gustav Carus, University of California [Irvine] (UCI), University of California, Service de Chirurgie Urologique [CHU Purpan - Toulouse], CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: medicine.medical_specialty, Consensus, Urology, 030232 urology & nephrology, curriculum, Certification, Session (web analytics), 03 medical and health sciences, Patient safety, 0302 clinical medicine, medicine, Curriculum development, Humans, Robotic surgery, Curriculum, robotics, validation, Medical education, education, training, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, Robotics, Focus group, Surgery, learning-needs, Content analysis, 030220 oncology & carcinogenesis, Urologic Surgical Procedures, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Objectives To explore the views of experts about the development and validation of a robotic surgery training curriculum, and how this should be implemented. Materials and methods An international expert panel was invited to a structured session for discussion. The study was of a mixed design, including qualitative and quantitative components based on focus group interviews during the European Association of Urology (EAU) Robotic Urology Section (ERUS) (2012), EAU (2013) and ERUS (2013) meetings. After introduction to the aims, principles and current status of the curriculum development, group responses were elicited. After content analysis of recorded interviews generated themes were discussed at the second meeting, where consensus was achieved on each theme. This discussion also underwent content analysis, and was used to draft a curriculum proposal. At the third meeting, a quantitative questionnaire about this curriculum was disseminated to attendees to assess the level of agreement with the key points. Results In all, 150 min (19 pages) of the focus group discussion was transcribed (21 316 words). Themes were agreed by two raters (median agreement kappa 0.89) and they included: need for a training curriculum (inter-rater agreement kappa 0.85); identification of learning needs (kappa 0.83); development of the curriculum contents (kappa 0.81); an overview of available curricula (kappa 0.79); settings for robotic surgery training ((kappa 0.89); assessment and training of trainers (kappa 0.92); requirements for certification and patient safety (kappa 0.83); and need for a universally standardised curriculum (kappa 0.78). A training curriculum was proposed based on the above discussions. Conclusion This group proposes a multi-step curriculum for robotic training. Studies are in process to validate the effectiveness of the curriculum and to assess transfer of skills to the operating room.
Published: 2015

18. Maternal and fetal outcomes of pregnancy with Fontan circulation: A multicentric observational study

Author: Guy Vaksmann, Elise Barre, Sassolas F, Fabien Labombarda, Laurianne Le Gloan, Marielle Gouton, Pascal Amedro, Maria Jimenez, Jelena Radojevic, Jacky Nizard, Magalie Ladouceur, Alain Chantepie, Amel Mathiron, Mehul Patel, Centre de Référence des Malformations Cardiaques Congénitales Complexes (M3C), Université Pierre et Marie Curie - Paris 6 (UPMC), Baylor College of Medicine (BCM), Baylor University, Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL), Clinique Saint Augustin, CHU Amiens-Picardie, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Rouen, Normandie Université (NU), CHRU Clocheville, Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Nord - Amiens, Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), and Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Adult, Heart Defects, Congenital, Male, Pediatrics, medicine.medical_specialty, Pregnancy Complications, Cardiovascular, 030204 cardiovascular system & hematology, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, 03 medical and health sciences, Anticoagulation, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Pregnancy, Fontan circulation, medicine, Humans, Twin Pregnancy, ComputingMilieux_MISCELLANEOUS, Retrospective Studies, Congenital heart disease, Fetus, 030219 obstetrics & reproductive medicine, business.industry, Obstetrics, Incidence, Incidence (epidemiology), Infant, Newborn, Pregnancy Outcome, Retrospective cohort study, medicine.disease, 3. Good health, Term Birth, Female, Maternal death, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, Cardiology and Cardiovascular Medicine, business, Infant, Premature, Postpartum period
Abstract: International audience; Background: Despite serious long-term sequel, women with Fontan palliation have reached childbearing age. However there is paucity of data on the pregnancy outcomes and management of this condition. We aimed to determine the maternal and fetal outcomes of pregnancy in women with Fontan palliation.Methods: This multicentric, retrospective study included women with Fontan circulation followed in 13 French specialized centers from January 2000 to June 2014. All pregnancies were reviewed, including miscarriages, abortions, premature and term births. We reviewed maternal and fetal outcomes.Results: Thirty-seven patients had 59 pregnancies. Mean age was 27 ± 5 years at first pregnancy. There were 16 miscarriages (27%) and 36 live births with 1 twin pregnancy. Cardiac events occurred in 6 (10%) pregnancies, with no maternal death. The most common cardiac complication was atrial arrhythmia, which occurred in 3 patients. Hematological complications including thromboembolic/hemorrhagic events (n = 3/7) occurred in 5 women antepartum (n = 2/3), and 4 women postpartum (n = 1/4). Two of the 3 thromboembolic events occurred in patients without anticoagulation. There was a high incidence of prematurity (n = 25/36, 69%). Anticoagulation was associated with adverse neonatal outcome (OR = 10.0, 95% CI [1.5–91.4], p < 0.01). After a median follow-up of 24 months, there was no significant worsening of clinical status and thromboembolic disease noted.Conclusions: Pre-selected women can successfully complete pregnancy with Fontan circulation. There is an increase in cardiac and neonatal morbidity during pregnancy. Because thromboembolism could have a severe consequence on Fontan circulation, anticoagulation should be indicated during pregnancy and postpartum period.
Published: 2015

19. Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma

Author: Nadine Houede, Camille Chakiba, Marine Gross-Goupil, François Cornelis, Edouard Descat, P. Sargos, Guilhem Roubaud, Département d'oncologie médicale, Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Clinique Saint Augustin, Département de radiothérapie [Bordeaux], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), and CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Subjects: Male, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, medicine.medical_treatment, Contrast Media, 030218 nuclear medicine & medical imaging, 0302 clinical medicine, Aged, 80 and over, medicine.diagnostic_test, General Medicine, Middle Aged, Magnetic Resonance Imaging, Neoadjuvant Therapy, 3. Good health, Treatment Outcome, 030220 oncology & carcinogenesis, Dynamic contrast-enhanced MRI, Biomarker (medicine), Female, Radiology, medicine.drug, MRI, Adult, medicine.medical_specialty, Therapeutic response, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, Neoadjuvant chemotherapy, Sensitivity and Specificity, 03 medical and health sciences, medicine, Carcinoma, Humans, Radiology, Nuclear Medicine and imaging, Pathological, Aged, Retrospective Studies, Cisplatin, Chemotherapy, Carcinoma, Transitional Cell, business.industry, Bladder carcinoma, Reproducibility of Results, Magnetic resonance imaging, Biomarker, Contrast, medicine.disease, Urinary Bladder Neoplasms, Potential biomarkers, Neoplasm Recurrence, Local, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Biomarkers
Abstract: Objectives To evaluate the performance of dynamic contrast enhanced (DCE) magnetic resonance (MR) imaging to assess the histological response after chemotherapy on bladder carcinoma. Methods From 2008 to 2010, 12 patients presenting localized urothelial carcinoma of the bladder were prospectively evaluated by DCE-MR imaging before and after two courses of cisplatin-based neoadjuvant chemotherapy. Size and thickness of tumours were measured. Relative enhancement at the arterial (rSI35s) and venous phases (rSI80s) of each tumour was obtained. Histological response was assessed and outcomes were recorded. Results Histological examination after neoadjuvant chemotherapy concluded as pathological complete response (pCR) for 6 out of 12 patients. Five patients developed recurrences (4/6 no pCR and 1/6 pCR). Significant differences, between before and after treatment, were found for patients with complete pathological response after chemotherapy for all MR quantitative values. Tumours decreased in size and thickness (both P = 0.03). After treatment, rSI80s was significantly different between pCR and non-pCR patients (P = 0.04) with a cut-off value of 40%. For this cut-off, sensitivity, specificity and accuracy were 83.33%. Similar recurrence free survivals were obtained if applying the MR cut-off value or the histopathological findings. Conclusion Our results suggest that DCE-MR imaging may be a useful biomarker for patients with localized bladder carcinoma, improving selection before surgery.
Published: 2014

20. Hemorrhagic cystitis in patients treated with cabazitaxel: a radiation recall syndrome?

Author: C. Dupin, Marine Gross-Goupil, Guilhem Roubaud, V. Lieutenant, Paul Sargos, N. Houede, C. Merino, Thomas Grellety, J. L. Hoepffner, J. Riviere, Pierre Richaud, Institut Bergonié [Bordeaux], UNICANCER, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), and Clinique Saint Augustin
Subjects: Male, medicine.medical_specialty, medicine.medical_treatment, Radiotherapy/*adverse effects, Radiation Injuries/complications, MEDLINE, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, Cystitis/*etiology, Radiation recall syndrome, Cystitis, Prostatic Neoplasms/*therapy, medicine, Humans, In patient, Radiation Injuries, Hematuria, Aged, Hematuria/*etiology, Radiotherapy, business.industry, Prostatic Neoplasms, Hematology, Middle Aged, Antineoplastic Agents/*adverse effects, medicine.disease, Surgery, Radiation therapy, Oncology, Cabazitaxel, Taxoids/*adverse effects, Taxoids, business, Hemorrhagic cystitis, medicine.drug
Published: 2014

21. Prise en charge du cancer du rein en 2007 : actualités et recommandations [Kidney cancer management in 2007: news and recommendations]

Author: Cornu, Jean-Nicolas, Rouprêt, Morgan, Lang, Hervé, Long, Jean-Alexandre, Neuzillet, Yann, Patard, Jean-Jacques, Piéchaud, Thierry, Corréas, Jean-Michel, de Fromont, Marc, Escudier, Bernard, Méjean, Arnaud, Service d'urologie et transplantation rénales [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Service d'urologie, CHU Strasbourg, CHU Grenoble-Hôpital Michallon, Service d'urologie et de transplantation rénale, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille ( APHM ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Clinique Saint Augustin, Service de Radiologie et imagerie médicale [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Département de pathologie, Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Département d'immunothérapie, Institut Gustave Roussy ( IGR ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Descartes - Paris 5 ( UPD5 ) -CHU Necker - Enfants Malades [AP-HP], Service d'urologie et transplantation rénales [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM), Service d'urologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Institut Gustave Roussy (IGR), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Service d'Urologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and De Villemeur, Hervé
Subjects: [ SDV.MHEP.UN ] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, [SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer
Abstract: International audience; In case of a single renal cell carcinoma strictly located in the kidney, the radical nephrectomy remains the treatment of choice. However, it has been estimated that nearly 30 to 40 % of renal cell carcinoma are about to recur after primitive surgery. In certain cases, conservative surgery can be discussed as an alternative to radical treatment, especially in case of exophytic renal tumour or less than 4 cm in diameter. New ablative techniques (radiofrequency and cryoablation) have shown promising results but the follow-up is still very limited. French national recommendation regarding kidney cancer have been updated in 2007 and following the development of clinical trials using antiangiogenic agents. Regarding the use of antiangiogenic agents, several points have to be taken into account: existence of renal cell carcinoma, presence of metastasis, number of metastasis, location and risk factor prognosis determination.
Published: 2008

22. The premaxilla in Neandertal and early modern children: ontogeny and morphology

Author: Bruno Maureille, Dominique Bar, De la Préhistoire à l'Actuel : Culture, Environnement et Anthropologie (PACEA), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Scanner, Clinique Saint Augustin, and Huchet, Jean-Bernard
Subjects: CT scan, Adult, Neanderthal, Premaxilla, premaxilla, Ontogeny, [SHS.ANTHRO-BIO]Humanities and Social Sciences/Biological anthropology, modern, 03 medical and health sciences, 0302 clinical medicine, Fetus, Suture (anatomy), Osteogenesis, biology.animal, medicine, Maxilla, Animals, Humans, 0601 history and archaeology, Human Paleontology, Child, Ecology, Evolution, Behavior and Systematics, 060101 anthropology, Bone Development, biology, Dentition, Fossils, Qafzeh, Hominidae, 030206 dentistry, 06 humanities and the arts, Anatomy, Synostosis, medicine.disease, Biological Evolution, [SHS.ANTHRO-BIO] Humanities and Social Sciences/Biological anthropology, Skull, medicine.anatomical_structure, ontogeny, Anthropology, Child, Preschool, Tomography, X-Ray Computed, Neandertal
Abstract: This comparative study of maxillae in Neandertals, Qafzeh, and extant children examines two specific traits: the premaxillary suture (sutura incisiva) and the interincisive sinuses, proposing a new hypothesis about some features of the Neandertal mid-face. Morphologic study of the premaxillary suture at its different borders (i.e. the nasal aspect of the frontal process, nasal and palatal aspects of the palatal process of the maxilla) indicates a persistence of the suture among very young Neandertal children in comparison to the condition in extant ones. This suggests a longer independence of some parts of the premaxilla in Neandertals. To further examine this possibility, CT scans of two Neandertal children were analyzed: Roc de Marsal, estimated to be about 3 years, and Engis 2, estimated to be about 5–6 years. The results are quite different between the fossils. In the older, the premaxillary suture is represented only by a deep groove. In the younger it extends deep to the surface of the nasal process reaching the Parinaud's canal. Synostosis of the premaxillary suture was found to occur later in Neandertal children than in modern ones. Moreover, we observed the existence of two interincisive sinuses in the fossil children, whereas this is rare in modern children (present on only 2% of our sample of 0–6 year-old infants, n=247). Persistence of an open premaxillary suture represents the potential for an extended period of growth of the Neandertal mid-face. Although no trace of the premaxillary suture remains in adult Neandertals, Neandertals present many features classically considered as consequences of this persistence. The two interincisive sinuses could be a consequence of the labio-lingual diameter of the incisors. The results presented here can be further investigated by additional studies on the cranial sutural system and by precise morphologic observations and CT scans of the mid-face of a larger sample of fossil children., L'étude de la région prémaxillaire, et plus précisément de deux caractères: la suture incisive et les sinus interincisifs, est menée de manière comparative chez les enfants néandertaliens, des sujets immatures de Qafzeh et d'enfants modernes. Elle nous permet de présenter une nouvelle hypothèse pour expliquer quelques caractéristiques de la partie médiale de la face néandertalienne. L'étude morphoscopique de la suture incisive selon ses différents sites d'expression (c'est-à-dire la face nasale du processus frontal, les faces nasale et palatine du processus palatin du maxillaire) montre la persistance de la suture chez les très jeunes enfants néandertaliens par rapport aux enfants modernes. Ce résultat permet de supposer que certaines parties du prémaxillaire avaient conservé une individualité plus importante chez les Néandertaliens. Pour approfondir cette étude, nous avons examiné des coupes scanners des maxillaires de deux enfants néandertaliens: Roc-de-Marsal (âgé de 3 ans) et Engis 2 (âgé de 5–6 ans). Les résultats de ces scanners diffèrent entre les deux fossiles. Chez le premier, la suture incisive est ouverte sur toute la hauteur de la voûte palatine et atteind le canal de Parinaud sur le processus frontal alors que chez le second elle est représentée uniquement par un profond sillon. Néanmoins, la synostose de la suture incisive a lieu plus tard chez les enfants néandertaliens que chez les enfants modernes. De plus, nous avons observé l'existence de deux sinus interincisifs sur les maxillaires immatures néandertaliens, l'existence de deux sinus est extrêmement rare sur les maxillaires modernes non pathologiques (seulement 2% des sujets entre 0 et 6 ans). Par conséquent, les potentialités de croissance de la région médiale de la face néandertalienne semblent être favorisées par le premier caractère. Bien qu'il ne reste aucune trace de la suture incisive chez les adultes néandertaliens, ceux-ci présentent un ensemble de caractères classiquement associés à une longue individualité du prémaxillaire pendant l'enfance. La seconde caractéristique pourrait être une conséquence du diamètre vestibulo-lingual des incisives. Cependant, cette hypothèse et les résultats obtenus devront être confirmés par des études complémentaires portant sur le système sutural du crâne, et par l'examen morphologique et scanographique de la partie médiale de la face d'un échantillon plus large de fossiles.
Published: 1999

23. Les crânes déformés de Saint-Etienne (Beaune, Côte d'Or, Ve-VIe siècles). Données archéologiques et anthropologiques

Author: Maureille, Bruno, Castex, Dominique, Depierre, Germaine, Bar, D., De la Préhistoire à l'Actuel : Culture, Environnement et Anthropologie (PACEA), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Archéologie, Terre, Histoire, Sociétés [Dijon] (ARTeHiS), Ministère de la Culture et de la Communication (MCC)-Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), Scanner, Clinique Saint Augustin, and HUCHET, Jean-Bernard
Subjects: cultural practices, pratiques funéraires, [SHS.ANTHRO-BIO]Humanities and Social Sciences/Biological anthropology, coupes scanographiques, Crânes déformés, CT scans, pratiques culturelles, deformed skulls, haut Moyen-Age, [SHS.ANTHRO-BIO] Humanities and Social Sciences/Biological anthropology, early Middle Age, funeral practices
Abstract: The sector of the Saint-Étienne necropolis (Beaune), reveals the existence of two clearly separated zones which are characterized by different funeral and cultural practices: tomb architecture, archaeological material and artificially deformed crania. This seems to provide evidence of two distinct groups. A preliminary morpho-metrical study of four skulls and the examination of several CT scans of three of them, allow us to confirm the presence of artificial antero-posterior cranial deformations., Le secteur de la nécropole Saint-Étienne (Beaune), sur lequel a porté notre étude, a révélé l'existence de deux zones nettement séparées se caractérisant par des pratiques funéraires et culturelles différentes : architecture des tombes, matériel d'accompagnement et crânes déformés artificiellement. Ces différences semblent témoigner de l'existence de deux groupes distincts. Une étude préliminaire morphométrique de quatre crânes ainsi que l'examen de plusieurs coupes scanographiques de trois d'entre eux, ont permis de confirmer l'existence de déformations crâniennes artificielles de type antéro-postérieur.
Published: 1995

24. THE DEFORMED SKULLS FROM SAINT-ÉTIENNE (BEAUNE, CÔTE D'OR, V™-VI™ CENTURIES). ARCHEOLOGICAL AND ANTHROPOLOGICAL DATA

Author: Bruno Maureille, Dominique Castex, Dominique Bar, Germaine Depierre, de la Préhistoire à l'Actuel, Cultures, Environnement, Anthropologie ( PACEA ), Université Sciences et Technologies - Bordeaux 1-Ministère de la Culture et de la Communication ( MCC ) -Centre National de la Recherche Scientifique ( CNRS ), Archéologie, Terre, Histoire, Sociétés [Dijon] ( ARTeHiS ), Ministère de la Culture et de la Communication ( MCC ) -Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ), Scanner, Clinique Saint Augustin, De la Préhistoire à l'Actuel : Culture, Environnement et Anthropologie (PACEA), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Archéologie, Terre, Histoire, Sociétés [Dijon] (ARTeHiS), and Ministère de la Culture et de la Communication (MCC)-Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)
Subjects: cultural practices, Cultural Studies, Archeology, pratiques funéraires, [SHS.ANTHRO-BIO]Humanities and Social Sciences/Biological anthropology, coupes scanographiques, Crânes déformés, haut Moyen-Age, early Middle Age, Anthropology, [ SHS.ANTHRO-BIO ] Humanities and Social Sciences/Biological anthropology, crânes déformés, haut Moyen Âge, pratiques culturelles, CT scans, deformed skulls, ComputingMilieux_MISCELLANEOUS, funeral practices
Abstract: Summary. — The sector of the Saint-Étienne necropolis (Beaune), reveals the existence of two clearly separated zones which are characterized by different funeral and cultural practices: tomb architecture, archaeological material and artificially deformed crania. This seems to provide evidence of two distinct groups. A preliminary morpho-metrical study of four skulls and the examination of several CT scans of three of them, allow us to confirm the presence of artificial antero-posterior, Résumé. — Le secteur de la nécropole Saint-Étienne (Beaune), sur lequel a porté notre étude, a révélé l'existence de deux zones nettement séparées se caractérisant par des pratiques funéraires et culturelles différentes : architecture des tombes, matériel d'accompagnement et crânes déformés artificiellement. Ces différences semblent témoigner de l'existence de deux groupes distincts. Une étude préliminaire morphométrique de quatre crânes ainsi que l'examen de plusieurs coupes scanographiques de trois d'entre eux, ont permis de confirmer l'existence de déformations crâniennes artificielles de type antéro-postérieur., Maureille Bruno, Castex Dominique, Depierre Germaine, Bar Dominique. Les crânes déformés de Saint-Étienne (Beaune, Côte d'Or, Ve-VIe siècles). Données archéologiques et anthropologiques. In: Bulletins et Mémoires de la Société d'anthropologie de Paris, Nouvelle Série. Tome 7 fascicule 1-2, 1995. pp. 49-67.
Published: 1995

25. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment?

Author: Baboudjian M, Diamand R, Uleri A, Beauval JB, Touzani A, Roche JB, Lacetera V, Roumeguère T, Simone G, Benamran D, Fourcade A, Gondran-Tellier B, Fiard G, Peltier A, and Ploussard G
Subjects: Humans, Male, Aged, Retrospective Studies, Middle Aged, Overtreatment, Prostatectomy, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Prostatic Neoplasms pathology, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms surgery, Neoplasm Grading, Image-Guided Biopsy methods
Abstract: Background and Objective: Targeted biopsy of the index prostate cancer (PCa) lesion on multiparametric magnetic resonance imaging (MRI) is effective in reducing the risk of overdiagnosis of indolent PCa. However, it remains to be determined whether MRI-targeted biopsy can lead to a stage shift via overgrading of the index lesion by focusing only on the highest-grade component, and to a subsequent risk of overtreatment. Our aim was to assess whether overgrading on MRI-targeted biopsy may lead to overtreatment, using radical prostatectomy (RP) specimens as the reference standard., Methods: Patients with clinically localized PCa who had positive MRI findings (Prostate Imaging-Reporting and Data System [PI-RADS] score ≥3) and Gleason grade group (GG) ≥2 disease detected on MRI-targeted biopsy were retrospectively identified from a prospectively maintained database that records all RP procedures from eight referral centers. Biopsy grade was defined as the highest grade detected. Downgrading was defined as lower GG for the RP specimen than for MRI-targeted biopsy. Overtreatment was defined as downgrading to RP GG 1 for cases with GG ≥2 on biopsy, or to RP low-burden GG 2 for cases with GG ≥3 on biopsy., Key Findings and Limitations: We included 1020 consecutive biopsy-naïve patients with GG ≥2 PCa on MRI-targeted biopsy in the study. Pathological analysis of RP specimens showed downgrading in 178 patients (17%). The transperineal biopsy route was significantly associated with a lower risk of downgrading (odds ratio 0.364, 95% confidence interval 0.142-0.814; p = 0.022). Among 555 patients with GG 2 on targeted biopsy, only 18 (3.2%) were downgraded to GG 1 on RP. Among 465 patients with GG ≥3 on targeted biopsy, three (0.6%) were downgraded to GG 1 and seven were downgraded to low-burden GG 2 on RP. The overall risk of overtreatment due to targeted biopsy was 2.7% (28/1020)., Conclusions and Clinical Implications: Our multicenter study revealed no strong evidence that targeted biopsy results could lead to a high risk of overtreatment., (Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
Published: 2024
Full Text: View/download PDF

26. Percutaneous coronary intervention for bifurcation coronary lesions using optimised angiographic guidance: the 18th consensus document from the European Bifurcation Club.

Author: Burzotta F, Louvard Y, Lassen JF, Lefèvre T, Finet G, Collet C, Legutko J, Lesiak M, Hikichi Y, Albiero R, Pan M, Chatzizisis YS, Hildick-Smith D, Ferenc M, Johnson TW, Chieffo A, Darremont O, Banning A, Serruys PW, and Stankovic G
Subjects: Humans, Coronary Vessels diagnostic imaging, Coronary Vessels surgery, Percutaneous Coronary Intervention methods, Coronary Angiography methods, Ultrasonography, Interventional methods, Ultrasonography, Interventional standards, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Consensus, Tomography, Optical Coherence methods
Abstract: The 2023 European Bifurcation Club (EBC) meeting took place in Warsaw in October, and the latest evidence for the use of intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to optimise percutaneous coronary interventions (PCI) on coronary bifurcation lesions (CBLs) was a major focus. The topic generated deep discussions and general appraisal on the potential benefits of IVUS and OCT in PCI procedures. Nevertheless, despite an increasing recognition of IVUS and OCT capabilities and their recognised central role for guidance in complex CBL and left main PCI, it is expected that angiography will continue to be the primary guidance modality for CBL PCI, principally due to educational and economic barriers. Mindful of the restricted access/adoption of intracoronary imaging for CBL PCI, the EBC board decided to review and describe a series of tips and tricks which can help to optimise angiography-guided PCI for CBLs. The identified key points for achieving an optimal angiography-guided PCI include a thorough analysis of pre-PCI images (computed tomography angiography, multiple angiographic views, quantitative coronary angiography vessel estimation), a systematic application of the technical steps suggested for a given selected technique, an intraprocedural or post-PCI use of stent enhancement and a low threshold for bailout use of intravascular imaging.
Published: 2024
Full Text: View/download PDF

27. Maintenance of beta-blockers and cardiac surgery-related outcomes: a prospective propensity-matched multicentre analysis.

Author: Guinot PG, Fischer MO, Nguyen M, Berthoud V, Decros JB, Besch G, and Bouhemad B
Subjects: Humans, Prospective Studies, Male, Female, Aged, Middle Aged, Treatment Outcome, Aged, 80 and over, Adrenergic beta-Antagonists therapeutic use, Atrial Fibrillation epidemiology, Atrial Fibrillation drug therapy, Cardiac Surgical Procedures adverse effects, Postoperative Complications epidemiology, Postoperative Complications prevention & control, Acute Kidney Injury epidemiology, Acute Kidney Injury prevention & control, Acute Kidney Injury etiology, Propensity Score
Abstract: Background: We investigated the effects of maintaining beta-blockers on the day of surgery on the incidence of atrial fibrillation and postoperative acute kidney injury (AKI) in patients undergoing cardiac surgery., Methods: We conducted a multicentre prospective observational study with propensity matching on patients treated with beta-blockers. We collected their baseline patient characteristics, comorbidities, and operative and postoperative outcomes. The endpoints were postoperative atrial fibrillation and AKI after cardiac surgery., Results: Of the 1789 included patients, propensity matching led to 583 patients in each group. Maintenance of beta-blockers was not associated with a reduced risk of atrial fibrillation (odds ratio: 0.86 [95% confidence interval 0.66-1.14], P=0.335; 141 patients [24.2%] vs 126 patients [21.6%]). Sensitivity analysis did not demonstrate association between beta-blocker maintenance and atrial fibrillation after cardiac surgery (odds ratio: 0.93 [95% confidence interval: 0.72-1.22], P=0.625). Maintenance of beta-blockers was associated with a higher rate of norepinephrine use (415 [71.2%] vs 465 [79.8%], P=0.0001) and postoperative AKI (124 [21.3%] vs 159 [27.3%], P=0.0127). No statistically significant difference was observed in ICU length of stay., Conclusions: Maintenance of beta-blockers on the day of surgery was not associated with a reduced incidence of postoperative atrial fibrillation. However, maintenance of beta-blockers was associated with increased usage of vasopressors, potentially contributing to adverse postoperative renal events., Clinical Trial Registration: NCT04769752., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Published: 2024
Full Text: View/download PDF

28. Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.

Author: Mjaess G, Haddad L, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Oderda M, Gontero P, Bernal-Gomez A, Mastrorosa A, Roche JB, Abou Zahr R, Ploussard G, Fiard G, Halinski A, Rysankova K, Dariane C, Delavar G, Anract J, Barry Delongchamps N, Bui AP, Taha F, Windisch O, Benamran D, Assenmacher G, Benijts J, Guenzel K, Roumeguère T, Peltier A, and Diamand R
Abstract: Background: Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions, identified through multiparametric magnetic resonance imaging (mpMRI), present a clinical challenge due to their equivocal nature in predicting clinically significant prostate cancer (csPCa). Aim of the study is to improve risk stratification of patients with PI-RADS 3 lesions and candidates for prostate biopsy., Methods: A cohort of 4841 consecutive patients who underwent MRI and subsequent MRI-targeted and systematic biopsies between January 2016 and April 2023 were retrospectively identified from independent prospectively maintained database. Only patients who have PI-RADS 3 lesions were included in the final analysis. A multivariable logistic regression analysis was performed to identify covariables associated with csPCa defined as International Society of Urological Pathology (ISUP) grade group ≥2. Performance of the model was evaluated using the area under the receiver operating characteristic curve (AUC), calibration, and net benefit. Significant predictors were then selected for further exploration using a Chi-squared Automatic Interaction Detection (CHAID) analysis., Results: Overall, 790 patients had PI-RADS 3 lesions and 151 (19%) had csPCa. Significant associations were observed for age (OR: 1.1 [1.0-1.1]; p = 0.01) and PSA density (OR: 1643 [2717-41,997]; p < 0.01). The CHAID analysis identified PSAd as the sole significant factor influencing the decision tree. Cut-offs for PSAd were 0.13 ng/ml/cc (csPCa detection rate of 1% vs. 18%) for the two-nodes model and 0.09 ng/ml/cc and 0.16 ng/ml/cc for the three-nodes model (csPCa detection rate of 0.5% vs. 2% vs. 17%)., Conclusions: For individuals with PI-RADS 3 lesions on prostate mpMRI and a PSAd below 0.13, especially below 0.09, prostate biopsy can be omitted, in order to avoid unnecessary biopsy and overdiagnosis of non-csPCa., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
Published: 2024
Full Text: View/download PDF

29. Impact of Bifurcation Involvement and Location in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the EuroCTO Registry.

Author: Moroni A, Ayoub M, Gorgulu S, Werner GS, Kalay N, Zaczkiewicz M, Wójcik J, Goktekin O, Tuner H, Woitek F, Arenz J, Gasparini GL, Drozd J, Boudou N, Schölzel BE, Diletti R, Avran A, Di Mario C, Mashayekhi K, and Agostoni P
Subjects: Humans, Male, Female, Aged, Europe epidemiology, Chronic Disease, Middle Aged, Ultrasonography, Interventional methods, Treatment Outcome, Coronary Vessels diagnostic imaging, Percutaneous Coronary Intervention methods, Registries, Coronary Occlusion surgery, Coronary Occlusion diagnosis, Coronary Angiography
Abstract: Bifurcation involvement close to or within the occluded segment poses increasing difficulties for chronic total occlusion (CTO)-percutaneous coronary intervention (PCI). However, this variable is not considered in the angiography-based CTO scoring systems nor has been extensively investigated in large multicenter series. Accordingly, we analyzed a CTO-PCI registry involving 92 European centers to explore the incidence, angiographic and procedural characteristics, and outcomes specific to CTO-PCIs with bifurcation involvement. A total of 3,948 procedures performed between January and November 2023 were examined (33% with bifurcation involvement). Among bifurcation lesions, 38% and 37% were located within 5 mm of the proximal and distal cap, respectively, 16% within the CTO body, and in 9% of cases proximal and distal bifurcations coexisted. When compared with lesions without bifurcation involvement, CTO bifurcation lesions had higher complexity (J-CTO 2.33 ± 1.21 vs 2.11 ± 1.27, p <0.001) and were associated with higher use of additional devices (dual-lumen microcatheter in 27.6% vs 8.4%, p <0.001, and intravascular ultrasound in 32.2% vs 21.7%, p <0.001). Radiation dose (1,544 [836 to 2,819] vs 1,298.5 [699.1 to 2,386.6] mGy, p <0.001) and contrast volume (230 [160 to 300] vs 190 [130 to 250] ml, p <0.001) were also higher. Technical success was similar (91.5% with bifurcation involvement vs 90.4% without bifurcation involvement, p = 0.271). However, the bifurcation lesions within the CTO segment (intralesion) were associated with lower technical success than the other bifurcation-location subgroups (83.7% vs 93.3% proximal, 93.4% distal, and 89.0% proximal and distal, p <0.001). On multivariable analysis, the presence of an intralesion bifurcation was independently associated with technical failure (odds ratio 2.04, 95% confidence interval 1.24 to 3.35, p = 0.005). In conclusion, bifurcations are present in approximately one-third of CTOs who underwent PCI. PCI of CTOs with bifurcation can be achieved with high success rates except for bifurcations within the occluded segment, which were associated with higher technical failure., Competing Interests: Declaration of competing interest Dr. Werner: speaker honoraria from Abbott Vascular, ASAHI Intecc, Daiichi-Sankyo, Orbus-Neich, Pfizer (New York, NY, United States), Philips-Volcano, and Siemens-Healthineers. TerumoWerner: speaker honoraria from Abbott Vascular, ASAHI Intecc, Daiichi-Sankyo, Orbus-Neich, Pfizer (New York, NY, United States), Philips-Volcano, Siemens-Healthineers, and Terumo. Myron Zaczkiewicz: speaker honoraria from Orbus-Neich, Medtronic, iVascular. Proctoring for Orbus-Neich and Asahi Intecc. Institutional: Abiomed. Dr. Boudou: minor fees as consultant from ASAHI Intecc and Terumo. Dr. Avran: proctoring for Boston Scientific, Biotronik, Vascular Therapy, ASAHI Intecc, Abbott Vascular, and Teleflex. Dr. Agostoni: consulting fees from Boston Scientific, CardiaWave, iVascular, Neovasc, Seven Sons, Teleflex, and Terumo. The remaining authors have no competing interests to declare., (Copyright © 2024 Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

30. Use of Beta-blockers in Major Surgery and Critical Care: The right use may be in the details.

Author: Fischer MO and Guinot PG
Published: 2024
Full Text: View/download PDF

31. External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratification.

Author: Diamand R, Guenzel K, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Bui AP, Taha F, Oderda M, Gontero P, Rysankova K, Bernal-Gomez A, Mastrorosa A, Roche JB, Fiard G, Abou Zahr R, Ploussard G, Windisch O, Novello Q, Benamran D, Delavar G, Anract J, Barry Delongchamps N, Halinski A, Dariane C, Vlahopoulos L, Assenmacher G, Roumeguère T, and Peltier A
Subjects: Humans, Male, Risk Assessment methods, Aged, Middle Aged, Image-Guided Biopsy methods, Predictive Value of Tests, Prostatic Neoplasms pathology, Prostatic Neoplasms diagnostic imaging, Magnetic Resonance Imaging methods, Prostate pathology, Prostate diagnostic imaging
Abstract: Purpose: Magnetic resonance imaging (MRI) is a promising tool for risk assessment, potentially reducing the burden of unnecessary prostate biopsies. Risk prediction models that incorporate MRI data have gained attention, but their external validation and comparison are essential for guiding clinical practice. The aim is to externally validate and compare risk prediction models for the diagnosis of clinically significant prostate cancer (csPCa)., Methods: A cohort of 4606 patients across fifteen European tertiary referral centers were identified from a prospective maintained database between January 2016 and April 2023. Transrectal or transperineal image-fusion MRI-targeted and systematic biopsies for PI-RADS score of ≥ 3 or ≥ 2 depending on patient characteristics and physician preferences. Probabilities for csPCa, defined as International Society of Urological Pathology (ISUP) grade ≥ 2, were calculated for each patients using eight models. Performance was characterized by area under the receiver operating characteristic curve (AUC), calibration, and net benefit. Subgroup analyses were performed across various clinically relevant subgroups., Results: Overall, csPCa was detected in 2154 (47%) patients. The models exhibited satisfactory performance, demonstrating good discrimination (AUC ranging from 0.75 to 0.78, p < 0.001), adequate calibration, and high net benefit. The model described by Alberts showed the highest clinical utility for threshold probabilities between 10 and 20%. Subgroup analyses highlighted variations in models' performance, particularly when stratified according to PSA level, biopsy technique and PI-RADS version., Conclusions: We report a comprehensive external validation of risk prediction models for csPCa diagnosis in patients who underwent MRI-targeted and systematic biopsies. The model by Alberts demonstrated superior clinical utility and should be favored when determining the need for a prostate biopsy., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Published: 2024
Full Text: View/download PDF

32. International consensus panel for transurethral resection of bladder tumours metrics: assessment of face and content validity.

Author: Paciotti M, Diana P, Gallioli A, De Groote R, Farinha R, Ficarra V, Gaston R, Gontero P, Hurle R, Martínez-Piñeiro L, Minervini A, Pansadoro V, Van Cleynenbreugel B, Wiklund P, Casale P, Lughezzani G, Uleri A, Mottrie A, Palou J, Gallagher AG, Breda A, and Buffi N
Abstract: Objective: To develop performance metrics that objectively define a reference approach to a transurethral resection of bladder tumours (TURBT) procedure, seek consensus on the performance metrics from a group of international experts., Methods: The characterisation of a reference approach to a TURBT procedure was performed by identifying phases and explicitly defined procedure events (i.e., steps, errors, and critical errors). An international panel of experienced urologists (i.e., Delphi panel) was then assembled to scrutinise the metrics using a modified Delphi process. Based on the panel's feedback, the proposed metrics could be edited, supplemented, or deleted. A voting process was conducted to establish the consensus level on the metrics. Consensus was defined as the panel majority (i.e., >80%) agreeing that the metric definitions were accurate and acceptable. The number of metric units before and after the Delphi meeting were presented., Results: A core metrics group (i.e., characterisation group) deconstructed the TURBT procedure. The reference case was identified as an elective TURBT on a male patient, diagnosed after full diagnostic evaluation with three or fewer bladder tumours of ≤3 cm. The characterisation group identified six procedure phases, 60 procedure steps, 43 errors, and 40 critical errors. The metrics were presented to the Delphi panel which included 15 experts from six countries. After the Delphi, six procedure phases, 63 procedure steps, 47 errors, and 41 critical errors were identified. The Delphi panel achieved a 100% consensus., Conclusion: Performance metrics to characterise a reference approach to TURBT were developed and an international panel of experts reached 100% consensus on them. This consensus supports their face and content validity. The metrics can now be used for a proficiency-based progression training curriculum for TURBT., (© 2024 BJU International.)
Published: 2024
Full Text: View/download PDF

33. New approach of classifying venous congestion in critically ill patients based on unsupervised machine-learning technique.

Author: Wong A, Mallat J, and Fischer MO
Subjects: Humans, Critical Illness, Hyperemia, Unsupervised Machine Learning
Published: 2024
Full Text: View/download PDF

34. MRI lesion size is more important than the number of positive biopsy cores in predicting adverse features and recurrence after radical prostatectomy: implications for active surveillance criteria in intermediate-risk patients.

Author: Baboudjian M, Uleri A, Beauval JB, Touzani A, Diamand R, Roche JB, Lacetera V, Lechevallier E, Roumeguère T, Simone G, Benamran D, Fourcade A, Fiard G, Peltier A, and Ploussard G
Subjects: Humans, Male, Aged, Middle Aged, Retrospective Studies, Magnetic Resonance Imaging methods, Neoplasm Grading, Multiparametric Magnetic Resonance Imaging, Prognosis, Neoplasm Staging, Prostate pathology, Prostate surgery, Prostate diagnostic imaging, Risk Factors, Watchful Waiting, Prostatic Neoplasms surgery, Prostatic Neoplasms pathology, Prostatic Neoplasms diagnostic imaging, Prostatectomy methods, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local epidemiology, Neoplasm Recurrence, Local diagnostic imaging, Tumor Burden
Abstract: Introduction: To determine associations between prostate cancer (PCa) tumor burden measured on biopsy or multiparametric magnetic resonance imaging (mpMRI) and outcomes in intermediate-risk (IR) International Society of Urological Pathology (ISUP) grade 2 men managed with primary radical prostatectomy (RP)., Methods: This retrospective, multicenter study was conducted in eight referral centers. The cohort included IR PCa patients who had ISUP 2 at biopsy. We defined biopsy tumor burden as low/high based on the absence/presence of more than 25% positive cores. Tumor burden on imaging was defined as low/high based on maximum lesion diameter, <15 mm and ≥15 mm at mpMRI, respectively. The histological endpoint of the study was adverse features at RP, defined as ≥pT3a stage and/or lymph node invasion and/or ISUP ≥3 at final pathology. The clinical endpoint was biochemical recurrence (BCR) after RP., Results: A total of 698 IR patients was included, of whom 335 (48%) had adverse features. In multivariate logistic regression analysis, there was no statistical association between tumor burden at biopsy and adverse features (p = 0.7). Tumor size ≥15 mm at mpMRI was significantly associated with adverse pathology (OR 1.65, 95%CI 1.14-2.39; p = 0.01). No significant association was observed between tumor burden at biopsy and BCR (p = 0.4). Tumor size ≥15 mm at mpMRI was significantly associated with BCR (HR 1.96, 95% CI 1.01-3.80; p = 0.04)., Conclusions: Our data support extending the inclusion criteria to ISUP 2 men with >25% positive cores, provided they have a low tumor size at mpMRI (<15 mm). Prospective studies should be performed to validate these findings., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
Published: 2024
Full Text: View/download PDF

35. How can we reduce morbidity after robot-assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group.

Author: Pellegrino F, Martini A, Falagario UG, Rautiola J, Russo A, Mertens LS, Di Gianfrancesco L, Bravi CA, Vollemaere J, Abdeen M, Moschini M, Mendrek M, Kjøbli E, Buse S, Wijburg C, Touzani A, Ploussard G, Antonelli A, Schwenk L, Ebbing J, Vasdev N, Froelicher G, John H, Canda AE, Balbay MD, Stoll M, Edeling S, Berquin C, Van Praet C, Leyh-Bannurah SR, Siemer S, Stoeckle M, Mottrie A, D'Hondt F, Crestani A, Porreca A, Briganti A, Montorsi F, van der Poel H, Dacaestecker K, Gaston R, Hosseini A, and Wiklund NP
Subjects: Humans, Urinary Bladder Neoplasms surgery, Urinary Diversion adverse effects, Urinary Reservoirs, Continent, Cystectomy methods, Cystectomy adverse effects, Robotic Surgical Procedures adverse effects, Postoperative Complications prevention & control
Published: 2024
Full Text: View/download PDF

36. Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol.

Author: Sargos P, Bellera C, Bentahila R, Guerni M, Benziane-Ouaritini N, Teyssonneau D, Vuong NS, Ploussard G, Roupret M, and Roubaud G
Abstract: Background: Combination of androgen deprivation therapy (ADT) with external beam radiation therapy (EBRT) is a standard of care for patients with intermediate-risk prostate cancer (PCa). However, 6 months of ADT generates multiple side effects impacting quality of life (QoL). Darolutamide (an androgen receptor targeting agent [ARTA]) is associated with low blood-brain barrier penetrance and less drug-drug interaction., Objective: To assess the efficacy of a combination of 6 months of darolutamide with EBRT to treat patients with unfavorable intermediate-risk PCa., Design, Setting, and Participants: The DARIUS trial is a multicenter randomized non comparative phase 2 trial, randomizing the 6-months darolutamide + EBRT arm versus 6-months ADT + EBRT in patients with unfavorable intermediate-risk PCa., Outcome Measurements and Statistical Analysis: The primary endpoint is a biological response defined as prostate-specific antigen ≤0.1 ng/ml at month six of darolutamide or ADT. The key secondary endpoints are biochemical recurrence-free survival, disease-free survival, safety, and QoL. Ancillary studies using radiomics and genomic classifier are planned. Sixty-two patients will be included., Results and Limitations: In this population of patients requiring ADT combined with EBRT, the use of an ARTA alone, such as darolutamide, may demonstrate antitumoral efficacy while minimizing toxicity and maintaining QoL. Limitations are mainly inherent to the open-label design of this study., Conclusions: Six months of darolutamide + EBRT compared with 6 months of ADT + EBRT may be efficient in terms of a biological response, avoiding toxicity and altered QoL attributable to ADT in patients with unfavorable intermediate-risk PCa., Patient Summary: The ongoing DARIUS clinical trial assesses short-term (6 months) darolutamide treatment in association with external beam radiation therapy in men with localized prostate cancer. The trial investigates whether single-agent darolutamide can improve the biological response while maintaining a favorable tolerability profile., (Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
Published: 2024
Full Text: View/download PDF

37. The impact of prostate volume estimation on the risk-adapted biopsy decision based on prostate-specific antigen density and magnetic resonance imaging score.

Author: Baudewyns A, Guenzel K, Halinski A, Dariane C, Delavar G, Anract J, Barry Delongchamps N, Jabbour T, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Oderda M, Gontero P, Bernal-Gomez A, Mastrorosa A, Roche JB, Zahr RA, Ploussard G, Fiard G, Rysankova K, Bui AP, Taha F, Windisch O, Benamran D, Vlahopoulos L, Assenmacher G, Roumeguère T, Peltier A, and Diamand R
Subjects: Humans, Male, Aged, Middle Aged, Organ Size, Risk Assessment, Image-Guided Biopsy methods, Magnetic Resonance Imaging methods, Clinical Decision-Making, Multiparametric Magnetic Resonance Imaging, Prospective Studies, Prostatic Neoplasms pathology, Prostatic Neoplasms diagnostic imaging, Prostate-Specific Antigen blood, Prostate pathology, Prostate diagnostic imaging
Abstract: Purpose: Utility of prostate-specific antigen density (PSAd) for risk-stratification to avoid unnecessary biopsy remains unclear due to the lack of standardization of prostate volume estimation. We evaluated the impact of ellipsoidal formula using multiparametric magnetic resonance (MRI) and semi-automated segmentation using tridimensional ultrasound (3D-US) on prostate volume and PSAd estimations as well as the distribution of patients in a risk-adapted table of clinically significant prostate cancer (csPCa)., Methods: In a prospectively maintained database of 4841 patients who underwent MRI-targeted and systematic biopsies, 971 met inclusions criteria. Correlation of volume estimation was assessed by Kendall's correlation coefficient and graphically represented by scatter and Bland-Altman plots. Distribution of csPCa was presented using the Schoots risk-adapted table based on PSAd and PI-RADS score. The model was evaluated using discrimination, calibration plots and decision curve analysis (DCA)., Results: Median prostate volume estimation using 3D-US was higher compared to MRI (49cc[IQR 37-68] vs 47cc[IQR 35-66], p < 0.001). Significant correlation between imaging modalities was observed (τ = 0.73[CI 0.7-0.75], p < 0.001). Bland-Altman plot emphasizes the differences in prostate volume estimation. Using the Schoots risk-adapted table, a high risk of csPCa was observed in PI-RADS 2 combined with high PSAd, and in all PI-RADS 4-5. The risk of csPCa was proportional to the PSAd for PI-RADS 3 patients. Good accuracy (AUC of 0.69 and 0.68 using 3D-US and MRI, respectively), adequate calibration and a higher net benefit when using 3D-US for probability thresholds above 25% on DCA., Conclusions: Prostate volume estimation with semi-automated segmentation using 3D-US should be preferred to the ellipsoidal formula (MRI) when evaluating PSAd and the risk of csPCa., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Published: 2024
Full Text: View/download PDF

38. Predicting contralateral extraprostatic extension in unilateral high-risk prostate cancer: a multicentric external validation study.

Author: Diamand R, Roche JB, Lacetera V, Simone G, Windisch O, Benamran D, Fourcade A, Fournier G, Fiard G, Ploussard G, Roumeguère T, Peltier A, and Albisinni S
Subjects: Humans, Male, Aged, Middle Aged, Risk Assessment, Retrospective Studies, Neoplasm Invasiveness, Algorithms, Extranodal Extension, Prostate pathology, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery, Prostatectomy methods
Abstract: Purpose: Accurate prediction of extraprostatic extension (EPE) is crucial for decision-making in radical prostatectomy (RP), especially in nerve-sparing strategies. Martini et al. introduced a three-tier algorithm for predicting contralateral EPE in unilateral high-risk prostate cancer (PCa). The aim of the study is to externally validate this model in a multicentric European cohort of patients., Methods: The data from 208 unilateral high-risk PCa patients diagnosed through magnetic resonance imaging (MRI)-targeted and systematic biopsies, treated with RP between January 2016 and November 2021 at eight referral centers were collected. The evaluation of model performance involved measures such as discrimination (AUC), calibration, and decision-curve analysis (DCA) following TRIPOD guidelines. In addition, a comparison was made with two established multivariable logistic regression models predicting the risk of side specific EPE for assessment purposes., Results: Overall, 38%, 48%, and 14% of patients were categorized as low, intermediate, and high-risk groups according to Martini et al.'s model, respectively. At final pathology, EPE on the contralateral prostatic lobe occurred in 6.3%, 12%, and 34% of patients in the respective risk groups. The algorithm demonstrated acceptable discrimination (AUC 0.68), comparable to other multivariable logistic regression models (p = 0.3), adequate calibration and the highest net benefit in DCA. The limitations include the modest sample size, retrospective design, and lack of central revision., Conclusion: Our findings endorse the algorithm's commendable performance, supporting its utility in guiding treatment decisions for unilateral high-risk PCa patients., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Published: 2024
Full Text: View/download PDF

39. How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity.

Author: Mailho C, Peyronnet B, De Seze M, Even A, Perrouin-Verbe MA, Amarenco G, Chartier-Kastler E, Le Normand L, Manunta A, Karsenty G, Kerdraon J, Ruffion A, Saussine C, Le Breton F, Bernuz B, Castel-Lacanal E, Denys P, Phé V, and Gamé X
Subjects: Humans, Quality of Life, Treatment Outcome, Urodynamics, Botulinum Toxins, Type A therapeutic use, Neuromuscular Agents therapeutic use, Urinary Bladder, Neurogenic etiology, Urinary Bladder, Overactive drug therapy, Urinary Incontinence complications
Abstract: Introduction: Neurogenic detrusor overactivity (NDO) has a major impact on patients' quality of life and can lead to upper urinary tract complications. Intradetrusor botulinum toxin type A injections are administered as second-line treatment to these patients following the failure of anticholinergic agents. The aim of the DETOX 2 study is to propose a consensus definition of the failure of intradetrusor botulinum toxin injections for NDO in patients presenting spinal cord injury, spina bifida, or multiple sclerosis (MS) with self-catheterization., Method: This study followed the method adopted by the French National Authority for Health for recommendations by consensus. Based on a review of the literature and a preliminary survey, a steering committee compiled a questionnaire and selected a rating group comprising 16 experts from the Neuro-Urology Committee of the French Urology Association (cnuAFU) and Genulf. The experts were asked to complete the online questionnaire. At the end of the first round, all participants came together to discuss any disagreements and a second-round online questionnaire was completed to reach a consensus., Results: Thirteen of the 16 experts approached completed both rounds of questionnaires. A strong consensus was reached for two proposals (median score = 9/10) which were therefore included in the definition from the first round: at least one repeat injection of the same botulinum toxin at the same dose must be given to rule out failure on technical grounds and a duration of efficacy <3 months must be considered a failure. At the end of round 2, a relative consensus was reached regarding the clinical criterion defining failure (median score = 7/10) and the urodynamic criterion of failure (median score = 8/10). An additional proposal was selected during this second round on the need for a voiding diary (median score = 8/10)., Conclusion: The first consensus definition of failure of an intradetrusor injection of TB-A for NDO has been achieved with this study: persistence of detrusor overactivity with maximum detrusor pressures >40 cm H 2 O and/or a compliance issue and/or persistence of urinary incontinence and/or urgency and/or a number of daily self-catheterizations >8/day and/or efficacy <3 months. This study will help to standardize research on the failure of the intradetrusor botulinum toxin for NDO in clinical practice and clinical research., (© 2024 Wiley Periodicals LLC.)
Published: 2024
Full Text: View/download PDF

40. Combination of computed tomography angiography with coronary artery calcium score for improved diagnosis of coronary artery disease: a collaborative meta-analysis of stable chest pain patients referred for invasive coronary angiography.

Author: Mohamed M, Bosserdt M, Wieske V, Dubourg B, Alkadhi H, Garcia MJ, Leschka S, Zimmermann E, Shabestari AA, Nørgaard BL, Meijs MFL, Øvrehus KA, Diederichsen ACP, Knuuti J, Halvorsen BA, Mendoza-Rodriguez V, Wan YL, Bettencourt N, Martuscelli E, Buechel RR, Mickley H, Sun K, Muraglia S, Kaufmann PA, Herzog BA, Tardif JC, Schütz GM, Laule M, Newby DE, Achenbach S, Budoff M, Haase R, Biavati F, Mézquita AV, Schlattmann P, and Dewey M
Subjects: Female, Humans, Male, Calcium, Chest Pain diagnosis, Computed Tomography Angiography methods, Coronary Angiography methods, Predictive Value of Tests, Tomography, X-Ray Computed methods, Middle Aged, Aged, Coronary Artery Disease diagnostic imaging, Coronary Stenosis diagnostic imaging
Abstract: Objectives: Coronary computed tomography angiography (CCTA) has higher diagnostic accuracy than coronary artery calcium (CAC) score for detecting obstructive coronary artery disease (CAD) in patients with stable chest pain, while the added diagnostic value of combining CCTA with CAC is unknown. We investigated whether combining coronary CCTA with CAC score can improve the diagnosis of obstructive CAD compared with CCTA alone., Methods: A total of 2315 patients (858 women, 37%) aged 61.1 ± 10.2 from 29 original studies were included to build two CAD prediction models based on either CCTA alone or CCTA combined with the CAC score. CAD was defined as at least 50% coronary diameter stenosis on invasive coronary angiography. Models were built by using generalized linear mixed-effects models with a random intercept set for the original study. The two CAD prediction models were compared by the likelihood ratio test, while their diagnostic performance was compared using the area under the receiver-operating-characteristic curve (AUC). Net benefit (benefit of true positive versus harm of false positive) was assessed by decision curve analysis., Results: CAD prevalence was 43.5% (1007/2315). Combining CCTA with CAC improved CAD diagnosis compared with CCTA alone (AUC: 87% [95% CI: 86 to 89%] vs. 80% [95% CI: 78 to 82%]; p < 0.001), likelihood ratio test 236.3, df: 1, p < 0.001, showing a higher net benefit across almost all threshold probabilities., Conclusion: Adding the CAC score to CCTA findings in patients with stable chest pain improves the diagnostic performance in detecting CAD and the net benefit compared with CCTA alone., Clinical Relevance Statement: CAC scoring CT performed before coronary CTA and included in the diagnostic model can improve obstructive CAD diagnosis, especially when CCTA is non-diagnostic., Key Points: • The combination of coronary artery calcium with coronary computed tomography angiography showed significantly higher AUC (87%, 95% confidence interval [CI]: 86 to 89%) for diagnosis of coronary artery disease compared to coronary computed tomography angiography alone (80%, 95% CI: 78 to 82%, p < 0.001). • Diagnostic improvement was mostly seen in patients with non-diagnostic C. • The improvement in diagnostic performance and the net benefit was consistent across age groups, chest pain types, and genders., (© 2023. The Author(s).)
Published: 2024
Full Text: View/download PDF

41. Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical Outcomes.

Author: Piramide F, Turri F, Amparore D, Fallara G, De Groote R, Knipper S, Wuernschimmel C, Bravi CA, Lambert E, Di Maida F, Liakos N, Pellegrino F, Andras I, Mastrorosa A, Tillu N, Mastroianni R, Paciotti M, Wenzel M, Bianchi R, di Trapani E, Moschovas MC, Gandaglia G, Moschini M, D'Hondt F, Rocco B, Fiori C, Galfano A, Minervini A, Simone G, Briganti A, De Cobelli O, Gaston R, Montorsi F, Breda A, Wiklund P, Porpiglia F, Mottrie A, Larcher A, and Dell'Oglio P
Abstract: Background: Multiple and heterogeneous techniques have been described for orthotopic neobladder (ONB) reconstruction after robot-assisted radical cystectomy. Nonetheless, a systematic assessment of all the available options is lacking., Objective: To provide the first comprehensive step-by-step description of all the available techniques for robotic intracorporeal ONB together with individual intraoperative, perioperative and functional outcomes based on a systematic review of the literature., Design, Setting, and Participants: We performed a systematic review of the literature, and MEDLINE/PubMed, Embase, Scopus, and Web of Science databases were searched to identify original articles describing different robotic intracorporeal ONB techniques and reporting intra- and perioperative outcomes. Studies were categorized according to ONB type, providing a synthesis of the current evidence. Video material was provided by experts in the field to illustrate the surgical technique of each intracorporeal ONB., Surgical Procedure: Nine different ONB types were identified: Studer, Hautmann, Y shape, U shape, Bordeaux, Pyramid, Shell, Florence Robotic Intracorporeal Neobladder, and Padua Ileal Neobladder., Measurements: Continuous and categorical variables are presented as mean ± standard deviation and as frequencies and proportions, respectively., Results and Limitations: Of 2587 studies identified, 19 met our inclusion criteria. No cohort studies or randomized control trials comparing different neobladder types are available. Available techniques for intracorporeal robotic ONB reconstruction have similar operative time, estimated blood loss, intraoperative complications, and length of stay. Major variability exists concerning postoperative complications and functional outcomes, likely related to reporting bias., Conclusions: Several techniques are described for intracorporeal ONB during robot-assisted radical cystectomy with comparable perioperative outcomes. We provide the first step-by-step surgical atlas for robot-assisted ONB reconstruction. Further comparative studies are needed to assess any advantage of one technique over others., Patient Summary: Patients elected for radical cystectomy should be aware that multiple techniques for robotic orthotopic neobladder are available, but that current evidence does not favor one type over the others., (Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
Published: 2024
Full Text: View/download PDF

42. [French national standard for the treatment of squamous cell carcinoma of upper aero-digestive tract - General principles of treatment].

Author: Barry B, Dolivet G, Clatot F, Huguet F, Abdeddaim C, Baujat B, Blanchard N, Calais G, Carrat X, Chatellier A, Coste F, Cupissol D, Cuvelier P, De Mones Del Pujol E, Deneuve S, Duffas O, Dupret-Bories A, Even C, Evrard C, Evrard D, Faivre S, Fakhry N, Garrel R, Gorphe P, Houliat T, Kaminsky MC, Krebs L, Lapeyre M, Lindas P, Malard O, Mirghani H, Mondina M, Moriniere S, Mouawad F, Pestre-Munier J, Pham Dang N, Picard A, Ramin L, Renard S, Salvan D, Schernberg A, Sire C, Thariat J, Vanbockstael J, Vo Tan D, Wojcik T, Klein I, Block V, Baumann-Bouscaud L, and De Raucourt D
Subjects: Humans, Gastrointestinal Tract, Carcinoma, Squamous Cell therapy
Abstract: Objectives: The management of upper aerodigestive tract cancers is a complex specialty. It is essential to provide an update to establish optimal care. At the initiative of the INCa and under the auspices of the SFORL, the scientific committee, led by Professor Béatrix Barry, Dr. Gilles Dolivet, and Dr. Dominique De Raucourt, decided to develop a reference framework aimed at defining, in a scientific and consensus-based manner, the general principles of treatment for upper aerodigestive tract cancers applicable to all sub-locations., Methodology: To develop this framework, a multidisciplinary team of practitioners was formed. A systematic analysis of the literature was conducted to produce recommendations classified by grades, in accordance with the standards of the French National Authority for Health (HAS)., Results: The grading of recommendations according to HAS standards has allowed the establishment of a reference for patient care based on several criteria. In this framework, patients benefit from differentiated care based on prognostic factors they present (age, comorbidities, TNM status, HPV status, etc.), conditions of implementation, and quality criteria for indicated surgery (operability, resectability, margin quality, mutilation, salvage surgery), as well as quality criteria for radiotherapy (target volume, implementation time, etc.). The role of medical and postoperative treatments was also evaluated based on specific criteria. Finally, supportive care must be organized from the beginning and throughout the patients' care journey., Conclusion: All collected data have led to the development of a comprehensive framework aimed at harmonizing practices nationally, facilitating decision-making in multidisciplinary consultation meetings, promoting equality in practices, and providing a state-of-the-art and reference practices for assessing the quality of care. This new framework is intended to be updated every 5 years to best reflect the latest advances in the field., (Copyright © 2024 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
Published: 2024
Full Text: View/download PDF

43. [National standard for the treatment of squamous cell carcinoma of upper aerodigestive tract].

Author: Dolivet G, Barry B, Abdeddaim C, Baujat B, Blanchard N, Calais G, Carrat X, Chatellier A, Clatot F, Coste F, Cupissol D, Cuvelier P, de Mones Del Pujol E, Deneuve S, Duffas O, Dupret-Bories A, Even C, Evrard C, Evrard D, Faivre S, Fakhry N, Garrel R, Gorphe P, Houliat T, Huguet F, Kaminsky MC, Krebs L, Lapeyre M, Lindas P, Malard O, Mirghani H, Mondina M, Moriniere S, Mouawad F, Pestre-Munier J, Pham Dang N, Picard A, Ramin L, Renard S, Salvan D, Schernberg A, Sire C, Thariat J, Vanbockstael J, Vo Tan D, Wojcik T, Klein I, Block V, Baumann-Bouscaud L, and de Raucourt D
Subjects: Humans, Carcinoma, Squamous Cell therapy, Carcinoma, Squamous Cell pathology, Head and Neck Neoplasms therapy
Published: 2024
Full Text: View/download PDF

44. Urodynamic Parameters and Continence Outcomes in Asymptomatic Patients with Ileal Orthotopic Neobladder: A Systematic Review and Metanalysis.

Author: Asimakopoulos AD, Finazzi Agrò E, Piechaud T, Gakis G, Gaston R, and Rosato E
Abstract: Introduction: The orthotopic neobladder is the type of urinary diversion (UD) that most closely resembles the original bladder. However, in the literature the urodynamic aspects are scarcely analysed., Objective: To provide the first systematic review (SR) on the urodynamic (UDS) outcomes of the ileal orthotopic neobladders (ONB). Continence outcomes are also presented., Methods: A PubMed, Embase and Cochrane CENTRAL search for peer-reviewed studies on ONB published between January 2001-December 2022 was performed according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement., Results and Conclusion: Fifty-nine manuscripts were eligible for inclusion in this SR. A great heterogeneity of data was encountered. Concerning UDS parameters, the pooled mean was 406.2 mL (95% CI: 378.9-433.4 mL) for maximal (entero)cystometric capacity (MCC) and 21.4 cmH 2 O (95% CI: 17.5-25.4 cmH 2 O) for Pressure ONB at MCC. Postvoid-residual ranged between 4.9 and 101.6 mL. The 12-mo rates of day and night-time continence were 84.2% (95% CI: 78.7-89.1%) and 61.7% (95% CI: 51.9-71.1%), respectively.Despite data heterogeneity, the ileal ONB seems to guarantee UDS parameters that resemble those of the native bladder. Although acceptable rates of daytime continence are reported the issue of high rates of night-time incontinence remains unsolved. Adequately designed prospective trials adopting standardised postoperative care, terminology and methods of outcome evaluation as well as of conduction of the UDS in the setting of ONB are necessary to obtain homogeneous follow-up data and to establish UDS guidelines for this setting.
Published: 2024
Full Text: View/download PDF

45. Transperineal or Transrectal Magnetic Resonance Imaging-targeted Biopsy for Prostate Cancer Detection.

Author: Diamand R, Guenzel K, Mjaess G, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Bui AP, Taha F, Oderda M, Gontero P, Rysankova K, Bernal-Gomez A, Mastrorosa A, Roche JB, Fiard G, Abou Zahr R, Ploussard G, Windisch O, Novello Q, Benamran D, Delavar G, Anract J, Barry Delongchamps N, Halinski A, Dariane C, Benijts J, Assenmacher G, Roumeguère T, and Peltier A
Abstract: Background and Objective: A notable paradigm shift has emerged in the choice of prostate biopsy approach, with a transition from transrectal biopsy (TRBx) to transperineal biopsy (TPBx) driven by the lower risk of severe urinary tract infections. The impact of this change on detection of clinically significant prostate cancer (csPCa) remains a subject of debate. Our aim was to compare the csPCa detection rate of TRBx and TPBx., Methods: Patients who underwent magnetic resonance imaging (MRI)-targeted and systematic biopsies for clinically localized PCa at 15 European referral centers from 2016 to 2023 were included. A propensity score matching (PSM) analysis was performed to minimize selection biases. Logistic regression models were used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs)., Key Findings and Limitations: Of 3949 patients who met the study criteria, 2187 underwent TRBx and 1762 underwent TPBx. PSM resulted in 1301 matched pairs for analysis. Patient demographics and tumor characteristics were comparable in the matched cohorts. TPBx versus TRBx was associated with greater detection of csPCa, whether defined as International Society of Urological Pathology grade group ≥2 (51% vs 45%; OR 1.37, 95% CI 1.15-1.63; p = 0.001) or grade group ≥3 (29% vs 23%; OR 1.38, 95% CI 1.13-1.67; p = 0.001). Similar results were found when considering MRI-targeted biopsy alone and after stratifying patients according to tumor location, Prostate Imaging-Reporting and Data System score, and clinical features. Limitations include the retrospective nature of the study and the absence of centralized MRI review., Conclusions: Our findings bolster existing understanding of the additional advantages offered by TPBx. Further randomized trials to fully validate these findings are awaited., Patient Summary: We compared the rate of detection of clinically significant prostate cancer with magnetic resonance imaging (MRI)-guided biopsies in which the sample needle is passed through the perineum or the rectum. Our results suggest that the perineal approach is associated with better detection of aggressive prostate cancer., (Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
Published: 2024
Full Text: View/download PDF

46. Experts' recommendations in laser use for the treatment of bladder cancer: a comprehensive guide by the European Section of Uro-Technology (ESUT) and Training and Research in Urological Surgery and Technology (TRUST)-Group.

Author: Ortner G, Güven S, Somani BK, Nicklas A, Teoh JY, Goumas IK, Bach T, Sancha FG, Figueredo FCA, Kramer MW, Bozzini G, Ulvik Ø, Kallidonis P, Roche JB, Miernik A, Enikeev D, Vaddi CM, Bhojani N, Sountoulides P, Lusuardi L, Baard J, Gauhar V, Ahmed A, Netsch C, Gözen AS, Nagele U, Herrmann TRW, and Tokas T
Subjects: Humans, Lasers, Technology, Thulium therapeutic use, Urinary Bladder Neoplasms surgery, Aluminum, Yttrium
Abstract: Purpose: To identify laser settings and limits applied by experts during laser vaporization (vapBT) and laser en-bloc resection of bladder tumors (ERBT) and to identify preventive measures to reduce complications., Methods: After a focused literature search to identify relevant questions, we conducted a survey (57 questions) which was sent to laser experts. The expert selection was based on clinical experience and scientific contribution. Participants were asked for used laser types, typical laser settings during specific scenarios, and preventive measures applied during surgery. Settings for a maximum of 2 different lasers for each scenario were possible. Responses and settings were compared among the reported laser types., Results: Twenty-three of 29 (79.3%) invited experts completed the survey. Thulium fiber laser (TFL) is the most common laser (57%), followed by Holmium:Yttrium-Aluminium-Garnet (Ho:YAG) (48%), continuous wave (cw) Thulium:Yttrium-Aluminium-Garnet (Tm:YAG) (26%), and pulsed Tm:YAG (13%). Experts prefer ERBT (91.3%) to vapBT (8.7%); however, relevant limitations such as tumor size, number, and anatomical tumor location exist. Laser settings were generally comparable; however, we could find significant differences between the laser sources for lateral wall ERBT (p = 0.028) and standard ERBT (p = 0.033), with cwTm:YAG and pulsed Tm:YAG being operated in higher power modes when compared to TFL and Ho:YAG. Experts prefer long pulse modes for Ho:YAG and short pulse modes for TFL lasers., Conclusion: TFL seems to have replaced Ho:YAG and Tm:YAG. Most laser settings do not differ significantly among laser sources. For experts, continuous flow irrigation is the most commonly applied measure to reduce complications., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Published: 2024
Full Text: View/download PDF

47. Passive leg raising test induced changes in plethysmographic variability index to assess fluid responsiveness in critically ill mechanically ventilated patients with acute circulatory failure.

Author: Mallat J, Lemyze M, and Fischer MO
Subjects: Humans, Respiration, Artificial, Leg, Critical Illness, Prospective Studies, Fluid Therapy, Cardiac Output, Hemodynamics, Shock
Abstract: Background: Passive leg raising (PLR) reliably predicts fluid responsiveness but requires a real-time cardiac index (CI) measurement or the presence of an invasive arterial line to achieve this effect. The plethysmographic variability index (PVI), an automatic measurement of the respiratory variation of the perfusion index, is non-invasive and continuously displayed on the pulse oximeter device. We tested whether PLR-induced changes in PVI (ΔPVI PLR ) could accurately predict fluid responsiveness in mechanically ventilated patients with acute circulatory failure., Methods: This was a secondary analysis of an observational prospective study. We included 29 mechanically ventilated patients with acute circulatory failure in this study. We measured PVI (Radical-7 device; Masimo Corp., Irvine, CA) and CI (Echocardiography) before and during a PLR test and before and after volume expansion of 500 mL of crystalloid solution. A volume expansion-induced increase in CI of >15% defined fluid responsiveness. To investigate whether ΔPVI PLR can predict fluid responsiveness, we determined areas under the receiver operating characteristic curves (AUROCs) and gray zones for ΔPVI PLR ., Results: Of the 29 patients, 27 (93.1%) received norepinephrine. The median tidal volume was 7.0 [IQR: 6.6-7.6] mL/kg ideal body weight. Nineteen patients (65.5%) were classified as fluid responders (increase in CI > 15% after volume expansion). Relative ΔPVI PLR accurately predicted fluid responsiveness with an AUROC of 0.89 (95%CI: 0.72-0.98, p < 0.001). A decrease in PVI ≤ -24.1% induced by PLR detected fluid responsiveness with a sensitivity of 95% (95%CI: 74-100%) and a specificity of 80% (95%CI: 44-97%). Gray zone was acceptable, including 13.8% of patients. The correlations between the relative ΔPVI PLR and changes in CI induced by PLR and by volume expansion were significant (r = -0.58, p < 0.001, and r = -0.65, p < 0.001; respectively)., Conclusions: In sedated and mechanically ventilated ICU patients with acute circulatory failure, PLR-induced changes in PVI accurately predict fluid responsiveness with an acceptable gray zone., Trial Registration: ClinicalTrials.govNCT03225378., Competing Interests: Declaration of Competing Interest The authors declare that they have no conflict of interests., (Copyright © 2023 Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

48. Heading toward a personalized approach for ECMO patient management.

Author: Fischer MO, Guinot PG, and Mallat J
Subjects: Humans, Precision Medicine, Extracorporeal Membrane Oxygenation
Published: 2024
Full Text: View/download PDF

49. NSAIDs for Pain Control During the Peri-Operative Period of Hip Fracture Surgery: A Systematic Review.

Author: Pommier W, Minoc EM, Morice PM, Lescure P, Guillaume C, Lafont C, Fischer MO, Boddaert J, Thietart S, Lelong-Boulouard V, Beauplet B, and Villain C
Abstract: Background: Hip fracture (HF) mostly affects older adults and is responsible for increased morbidity and mortality. Non-steroidal anti-inflammatory drugs (NSAIDs) are part of the peri-operative multimodal analgesic management, but their use could be associated with adverse events in older adults. This systematic review aimed to assess outcomes associated with NSAIDs use in the peri-operative period of HF surgery., Methods: This systematic review was conducted according to the PRISMA guidelines. Three databases (PubMed/EMBASE/Cochrane Central) were used to search for clinical trials and observational studies assessing efficacy, safety and impact of NSAIDs use on non-specific post-operative outcomes, such as functional status and post-operative complications., Results: Among the 1320 references initially identified, four provided data on efficacy, four on safety and six on non-specific post-operative outcomes (three randomized controlled clinical trials, three observational studies). Mean study population ages ranged from 68 to 87 years. Two studies found that NSAIDs were effective on pain control, but two studies found conflicting results on opioid sparing. No increased risk of acute kidney injury was observed, while results concerning bleeding risk and delirium were conflicting. No study has found any effect of NSAIDs use on walk recovery. Quality of evidence was high for pain control, but low to very low for all the other studied outcomes., Conclusions: The use of NSAIDs may be effective for pain control in the peri-operative period of HF surgery. However, safety data were conflicting with low levels of certainty. Further studies are needed to assess their benefit-risk balance in this context. The research protocol was previously registered on PROSPERO (registration number: CRD42021237649)., (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
Published: 2024
Full Text: View/download PDF

50. The long-term effect of a lung-ultrasound intervention on the risk for death, heart failure and myocardial infarction in dialysis patients.

Author: Torino C, Mallamaci F, Sarafidis P, Papagianni A, Ekart R, Hojs R, Klinger M, Letachowicz K, Fliser D, Seiler-Mußler S, Lizzi F, Siamopoulos K, Balafa O, Ntounousi E, Slotki I, Shavit L, Stavroulopoulos A, Massy ZA, Seidowsky A, Battaglia Y, Martinez-Castelao A, Villalobos G, Fiaccadori E, Regolisti G, Hannedouche T, Bachelet T, Jager KJ, Dekker FW, Tripepi R, Tripepi G, Gargani L, Sicari R, Picano E, London GM, and Zoccali C
Subjects: Humans, Renal Dialysis adverse effects, Lung, Myocardial Infarction etiology, Heart Failure
Published: 2024
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

236 results on '"Clinique Saint Augustin"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources